AstraZeneca PLC
Table of Contents
AstraZeneca PLC- Financial and Strategic Analysis Review ........................................3
Company Overview....................................................................................................3
AstraZeneca PLC- Key Facts .....................................................................................3
AstraZeneca PLC- Business Description ...................................................................3
AstraZeneca PLC- Major Products and Services .......................................................5
AstraZeneca PLC- History .........................................................................................6
AstraZeneca PLC- SWOT Analysis.........................................................................41
AstraZeneca PLC- Strengths ....................................................................................42
Strengths-Widespread geographic presence reduces business risks ....................42
Strengths-Significant R&D capabilities and manufacturing and supply resources42
Strengths-Sustained revenue growth attracts new and potential investors...........42
AstraZeneca PLC- Weaknesses................................................................................43
Weaknesses-Huge liabilities pose operational risk ..............................................43
AstraZeneca PLC- Opportunities .............................................................................43
Opportunities-Drug approvals likely to help the company in generating
incremental revenue .............................................................................................43
Opportunities-Strategic acquisitions are likely to help the company in expanding
its presence in market ...........................................................................................43
Opportunities-Positive outlook for global pharmaceutical industry ....................44
AstraZeneca PLC- Threats .......................................................................................44
Threats-Uncertain R&D outcomes .......................................................................44
Threats-Influx of generics ....................................................................................44
Threats-Regulation in different countries might hamper revenue growth ...........44
AstraZeneca PLC- Key Competitors........................................................................45
AstraZeneca PLC- Key Employees..........................................................................45
AstraZeneca PLC- Company Statement...................................................................50
AstraZeneca PLC- Locations & Subsidiaries...........................................................52
Head office ...........................................................................................................52
Other Locations & Subsidiaries ...............................................................................52
AstraZeneca PLC, Other locations.......................................................................52
AstraZeneca PLC, Subsidiaries................................................................................52
AstraZeneca Canada Inc.......................................................................................52
AstraZeneca A/S...................................................................................................53
AstraZeneca AS....................................................................................................53
AstraZeneca Pharma Poland Sp. z o.o. ................................................................53
Summarized Statement.............................................................................................53
AstraZeneca PLC, Annual Statements .....................................................................53
Income Statements ...............................................................................................53
Balance Sheet .......................................................................................................53
Cash Flow.............................................................................................................54
Detailed Statement ...................................................................................................54
AstraZeneca PLC, Full Annual Statements..............................................................54
Income Statements ...............................................................................................54
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 1
AstraZeneca PLC
Balance Sheet .......................................................................................................55
Cash Flow.............................................................................................................56
Summarized Interim Statement ................................................................................57
AstraZeneca PLC, Summarized Interim Statements................................................57
Balance Sheet .......................................................................................................57
Cash Flow.............................................................................................................57
Detailed Interim Statement.......................................................................................57
AstraZeneca PLC, Detailed Interim Statement ........................................................57
Balance Sheet .......................................................................................................58
Cash Flow.............................................................................................................59
Capital Market Ratios...............................................................................................60
AstraZeneca PLC, Capital Market Ratios ................................................................60
Interim Ratios ...........................................................................................................60
AstraZeneca PLC, Interim Ratios ............................................................................60
Annual Ratios ...........................................................................................................61
AstraZeneca PLC, Annual Ratios ............................................................................61
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 2
AstraZeneca PLC
AstraZeneca PLC- Financial and Strategic Analysis
Review
Company Overview
AstraZeneca PLC (AstraZeneca or 'the company') is a manufacturer, developer, and
marketer of prescription pharmaceuticals. The company provides drugs for various
therapeutic areas, including oncology, cardiovascular, renal and metabolic disease
(CVRM), respiratory, inflammation and autoimmunity, infection and vaccines, and
neuroscience. AstraZeneca markets its products under Accolate, Casodex, Byetta,
Diprivan, Faslodex, Zoladex, Tagrisso, Iressa, Symbicort, Pulmicort, Lynparza,
Nexium, and Onglyza brand names. The company sells its products to specialty care
and primary care physicians through wholly-owned local marketing companies, local
representative offices and distributors. It has business presence across the Americas,
Africa, Europe, and Asia. The company is headquartered in Cambridge,
Cambridgeshire, the UK.
AstraZeneca PLC- Key Facts
AstraZeneca PLC- Key Facts
Corporate
1 Francis Crick Avenue
Address
Ticker Symbol,
AZN[LON]
Exchange
No. of
Telephone
44 20 73045000
83500
Employees
Fiscal Year
Fax
N/A
December
End
Revenue (in
URL
www.astrazeneca.com/Home
44351
US$ Million)
Source : GlobalData Research analysis / © GlobalData Research
AstraZeneca PLC- Business Description
AstraZeneca PLC (AstraZeneca or 'the company') is a biopharmaceutical company
that develops, manufactures and markets prescription pharmaceuticals and biological
products in the therapeutic areas of cardiovascular, gastrointestinal, infection,
neuroscience, oncology and respiratory. The company sells its products to specialty
care and primary care physicians through wholly-owned local marketing companies,
local representative offices and distributors. The company operates across the
Americas, Europe, Africa, Asia, and other regions of the world.
The company generates revenue from two sources, including Product Sales and
Collaboration Revenue.
Under the product sales source, the company develops and markets prescription
pharmaceuticals. It offers these products under Faslodex (breast cancer); Iressa
(advanced NSCLC); Tagrisso (metastatic EGFR T790M mutation-positive NSCLC);
Lynparza (recurrent ovarian cancer and gBRCA HER2-negative metastatic breast
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 3
AstraZeneca PLC
cancer); Brilinta (post myocardial infarction and acute coronary syndromes); Farxiga
(Type 2 diabetes); Crestor (dyslipidaemia and hypercholesterolaemia); Pulmicort
(asthma); Nexium (acid-related diseases); Symbicort (asthma and COPD); and
Synagis (RSV infection in pediatric patients) brand names. These products are used to
treat cancer, renal and metabolic disease, cardiovascular, respiratory diseases and
other diseases.
The Product Sales business of the company is further divided into four therapeutic
areas, such as Oncology, Biopharmaceuticals, Rare Disease, and Other Medicines and
COVID-19.
The company's Oncology category provides products such as Arimidex (anastrozole);
Faslodex (fulvestrant); Cosodex (bicalutamide); Imfinzi (durvalumab), Tagrisso
(osimertinib); Iressa (gefitinib); Zoladex (goserelin acetate implant); Calquence
(acalabrutinib); and Lynparza (olaparib).
The Biopharmaceuticals category comprises cardiovascular, renal and metabolism
(CVRM) and respiratory and immunology (R&I). Under the cardiovascular, renal and
metabolic categories, the company provides the products such as Crestor (rosuvastatin
calcium), Atacand/Atacand HCT/Atac and Plus (candesartan cilexetil), Seloken ZOK,
Toprol-XL (metoprolol succinate); Plendil (felodipine); Zestril (lisinoprildihydrate);
Brilinta/Brilique (ticagrelor); Tenormin (atenolol); and Zestril (lisinoprildihydrate). It
also offers Byetta (exenatide injection) and Bydureon (exenatide extended release
injectable suspension); Forxiga/Farxiga (dapagliflozin); Kombiglyze XR (saxagliptin
and metformin XR); Komboglyze (saxagliptin and metformin HCl); Onglyza
(saxagliptin); Symlin (pramlintide acetate); Xigduo (dapagliflozin and metformin
hydrochloride); and Xigduo XR (dapagliflozin and metformin hydrochloride
extended-release). The R&I category offers Accolate (zafirlukast), Bevespi
Aerosphere (glycopyrrolate and formoterol fumarate), Bricanyl Respules
(terbutaline), Bricanyl Turbuhaler(terbutaline), Daliresp/Daxas(roflumilast), Duaklir
Genuair (aclidinium/formoterol), Eklira Genuair/Tudorza Pressair(aclidinium),
Fasenra (benralizumab), OxisTurbuhaler (formoterol), Pulmicort Turbuhaler/
PulmicortFlexhaler (budesonide), Pulmicort Respules (budesonide), Symbicortp MDI
(budesonide/formoterol), and Symbicort Turbuhaler (budesonide/formoterol).
The Rare Disease category comprises Soliris (eculizumab), Ultomiris (ravulizumab),
Strensiq (asfotase alfa), Ondexxya (andexanet alfa)/ Andexxa (coagulation factor Xa
(recombinant), inactivated-zhzo) and Kanuma (sebelipase alfa).
Under the Other Other Medicines and COVID-19 category, the company provides
products for infection, neuroscience, and gastrointestinal therapeutic areas.
AstraZeneca's gastrointestinal products include Losec/Prilosec (omeprazole) and
Nexium (esomeprazole). In the neuroscience therapeutic area, AstraZeneca offers,
Seroquel IR (quetiapine fumarate); Synagis (palivizumab), Seroquel XR (quetiapine
fumarate); Diprivan (propofol); EMLA; Naropin (ropivacaine); Vimovo
(naproxen/esomeprazole magnesium); Xylocaine (lidocaine); and Zomig
(zolmitriptan). In the infection and other therapeutic area, the company offers Synagis
(palivizumab); and Fluenz Tetra/FluMist Quadrivalent (live attenuated influenza
vaccine).
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 4
AstraZeneca PLC
In FY2021, the BioPharmaceuticals category accounted for 38% of Product Sales
total revenue, followed by Oncology (36%), Other Medicines and COVID-19 (17%),
and Rare Disease (8%).
In FY2021, the Product Sales reported revenue of US$36,541 million, which
accounted for 97.7% of the company’s total revenue.
The Collaboration source comprises the development, markets and collaboration
revenue such as receipts and royalties. In FY2021, the Collaboration reported revenue
of US$876 million, which accounted for 2.3% of the company’s total revenue.
Geographically, the company classifies its business operations in four regions: the
Americas; Asia, Africa and Australasia; Rest of Europe; and the UK. In FY2021, the
Americas accounted for 37.5% of the company’s revenue, followed by Asia, Africa
and Australasia (32.9%), Rest of Europe (20.9%) and the UK (8.7%).
AstraZeneca PLC- Major Products and Services
AstraZeneca PLC- Major Products and Services
Products:
Brands:
Gastrointestinal
Infection
Respiratory,
inflammation
and
autoimmunity
Oncology
Neuroscience
Cardiovascular
and metabolism
Bricanyl
Brilinta
Brilique
Bydureon
Byetta
Caprelsa
Casodex
Crestor
Diprivan
EMLA
Entocort
Farxiga
Faslodex
Fluenz
FluMist
Forxiga
Iressa
Kombiglyze/Komboglyze
Losec
Meronem
Merrem
Naropin
Nexium
Nolvadex
Onglyza
Oxis
Plendil
Prilosec
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 5
AstraZeneca PLC
Pulmicort
Rhinocort
Seloken
Seroquel
Symbicort
Symlin
Tenormin
Toprol-XL
Turbuhaler
Vimovo
Xigduo
Xylocaine
Zestril
Zoladex
Zomig
Xigduo
Lynparza
Duaklir
Eklira
Genuair/Tudorza/Bretaris
Accolate
Arimidex
Atacand
Axanum
Source : GlobalData Research analysis / © GlobalData Research
AstraZeneca PLC- History
AstraZeneca PLC- History
Year Event
2023 Contracts/Agreements
2023 Contracts/Agreements
2023 Contracts/Agreements
2023 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Description
In June, AstraZeneca entered into a
collaboration with Quell Therapeutics to
develop, manufacture and commercialize
engineered T-regulatory cell therapies for
autoimmune diseases.
In February, AstraZeneca and KYM
Biosciences Inc entered into a global
exclusive licence agreement for CMG901.
In September, AstraZeneca entered into a 15year partnership with Future Biogas to
establish unsubsidised industrial-scale supply
of biomethane gas.
In August, AstraZeneca received approval
from National Medical Products
Administration for Forxiga (dapagliflozin) to
reduce the risk of cardiovascular mortality,
hospital admission for heart failure or urgent
HF visits.
Page 6
AstraZeneca PLC
2023 Contracts/Agreements
In May, AstraZeneca and LaNova Medicines
entered a licence deal for La Nova’s LM-305.
2023 Contracts/Agreements
In June, AstraZeneca entered into a
partnership with Vanguard Renewables to
enable the delivery of renewable natural gas to
all of its sites in the US by the end of 2026.
2023 Regulatory Approval
In June, AstraZeneca announced that Soliris
secured an approval in China for the treatment
of adult patients with refractory generalised
myasthenia gravis.
2023 Contracts/Agreements
In January, AstraZeneca and Thermo Fisher
Scientific collaborated on the development of
a new solid tissue and blood-based companion
diagnostic (CDx) test for Tagrisso.
2023 Contracts/Agreements
In August, AstraZeneca entered into a
partnership with Qureight to accelerate
research into lung diseases using AI models.
2023 Contracts/Agreements
In August, AstraZeneca AB entered into an
agreement with CanSino Biologics under
which CanSino Biologics will provide
contract development and production services
to support its mRNA vaccine project,
production and supply certain products and
provide related certain services.
2023 Plans/Strategy
In June, AstraZeneca announced its plans to
spin off its China business.
2023 Contracts/Agreements
In June, AstraZeneca announced a
collaboration with Cholesgen (Shanghai) to
advance research and development in
hypercholesterolemia and related metabolic
diseases.
2023 Acquisitions/Mergers/Takeovers In January, AstraZeneca acquired Neogene
Therapeutics Inc., a clinical-stage
biotechnology company.
2023 Regulatory Approval
In June, AstraZeneca’s Xigduo XR
(dapagliflozin and metformin hydrochloride
extended-release) was approved by China’s
National Medical Products Administration for
the treatment of adults with type-2 diabetes.
2023 Contracts/Agreements
In September, AstraZeneca entered into a
research collaboration with Illumina, Inc. to
accelerate drug target discovery.
2023 Contracts/Agreements
In January, AstraZeneca and C2i Genomics
collaborated to evaluate the potential of
whole-genome minimal residual disease
(MRD) testing across solid cancers.
2023 Contracts/Agreements
In May, AstraZeneca entered into a license
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 7
AstraZeneca PLC
agreement with Revvity, Inc. for nextgeneration base editing technology.
2023 Contracts/Agreements
In July, AstraZeneca and Alexion entered into
an agreement to acquire a portfolio of
preclinical gene therapy programmes and
enabling technologies from Pfizer Inc.
2023 Contracts/Agreements
In October, AstraZeneca entered into a
licensing agreement with Nanoform Finland
under which Nanoform will receive access to
compound libraries and large data sets to
undertake STARMAP screening and propose
innovative product development concepts.
2023 Contracts/Agreements
In May, AstraZeneca entered into a
multifaceted research agreement with Kiyatec
to assess therapeutic efficacy of undisclosed
preclinical assets using Kiyatec’s 3D spheroid
screening platform, KIYA-Predict.
2023 Contracts/Agreements
In February, AstraZeneca collaborated with
SOPHiA GENETICS for the development of
oncology drugs.
2023 Financing Agreements
In June, AstraZeneca announced a US$400
million investment in its global AZ Forest
programme.
2023 Acquisitions/Mergers/Takeovers In February, AstraZeneca acquired CinCor
Pharma Inc., a clinical-stage
biopharmaceutical company.
2022 Regulatory Approval
In August, AstraZeneca announced that FDA
granted approval for adult patients with
chronic lymphocytic leukemia, small
lymphocytic lymphoma and relapsed or
refractory mantle cell lymphoma.
2022 Contracts/Agreements
In August, AstraZeneca and Daiichi Sankyo
partnered for clinical activity in patients with
advanced non-small cell lung cancer.
2022 Contracts/Agreements
In November, AstraZeneca and C4X
Discovery entered into a global licensing
agreement to develop oral therapy to treat
inflammatory and respiratory ailments.
2022 Divestiture
In March, AstraZeneca sold its AMAZE
disease management platform to Huma
Therapeutics Ltd.
2022 Acquisitions/Mergers/Takeovers In August, AstraZeneca acquired TeneoTwo
Inc, a biotechnology firm.
2022 Acquisitions/Mergers/Takeovers In November, Alexion, AstraZeneca Rare
Disease acquired LogicBio Therapeutics, a
genomic medicine company.
2022 Contracts/Agreements
In July, AstraZeneca UK Ltd entered into a
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 8
AstraZeneca PLC
three-year agreement with Oxford Biomedica
to manufacture its Covid-19 vaccine.
2022 Contracts/Agreements
In December, AstraZeneca and G42
Healthcare partnered to manufacture
pharmaceutical products in Abu Dhabi.
2022 Regulatory Approval
In September, AstraZeneca’s IMFINZI
(durvalumab) was approved in the US for the
treatment of adult patients with locally
advanced or metastatic biliary tract cancer
(BTC) in combination with chemotherapy
(gemcitabine plus cisplatin).
2021 Financing Agreements
In May, AstraZeneca invested US$40 million
in Silence Therapeutics plc.
2021 Contracts/Agreements
In June, AstraZeneca and ProAxsis Limited
entered into a licensing agreement for
COVID-19 serology test.
2021 Contracts/Agreements
In February, AstraZeneca and Amoy
Diagnostics Co Ltd entered into a
collaboration to develop a Homologous
Recombination Deficiency (HRD) Companion
Diagnostic (CDx) for ovarian cancer.
2021 Contracts/Agreements
In January, AstraZeneca and Adaptive
Biotechnologies Corporation entered into a
translational collaboration to investigate the
use of immunoSEQ T-MAP.
2021 Contracts/Agreements
In February, AstraZeneca entered into a
collaboration with Matrix Medical Network to
accelerate a clinical trial in the US for
AZD7442, a long-acting monoclonal antibody
for the prevention of COVID-19.
2021 Contracts/Agreements
In July, AstraZeneca's affiliate, MedImmune
Limited and EnWave Corporation signed a
material transfer agreement to trial EnWave’s
Radiant Energy Vacuum technology for the
dehydration of liquid monoclonal antibody
formulations.
2021 Contracts/Agreements
In April, AstraZeneca selected Reify Health’s
patient enrolment management platform,
StudyTeam, to accelerate clinical development
across its breast cancer investigational therapy
portfolio.
2021 Acquisitions/Mergers/Takeovers In November, AstraZeneca agreed to transfer
its global rights of Eklira and Duaklir
medicines to Covis Pharma for US$270
million.
2021 Acquisitions/Mergers/Takeovers In July, AstraZeneca completed the
acquisition of Alexion Pharmaceuticals Inc, a
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 9
AstraZeneca PLC
2021 Regulatory Approval
2021 Contracts/Agreements
2021 Regulatory Approval
2021 Plans/Strategy
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 New Product Approvals
2021 Contracts/Agreements
2021 Regulatory Approval
2021 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
pharmaceutical company.
In July, AstraZeneca received regulatory
approval from The UK Competition and
Markets Authority for proposed acquisition of
Alexion Pharmaceuticals, Inc.
In July, AstraZeneca and Regeneron entered
into a collaboration to research, develop and
commercialise new small molecule medicines
to treat obesity.
In June, AstraZeneca and MSD received
conditional approval for Lynparza (olaparib)
in China from China's National Medical
Products Administration to treat adult patients
with germline or somatic BRCA-mutated
metastatic castration-resistant prostate cancer.
In September, AstraZeneca announced to
invest US$360 million in the advanced
manufacturing facility to be built in Dublin,
Ireland.
In September, AstraZeneca entered into a
partnership with Thermo Fisher Scientific's
clinical sequencing business to develop nextgeneration sequencing-based companion
diagnostics.
In September, AstraZeneca entered into a
collaboration with VaxEquity to develop and
commercialize a self-amplifying RNA
therapeutics platform.
In April, the company and Geneseeq
Technology signed a strategic collaboration to
establish a Bio-Diagnostic Innovation Center
in Guangzhou, China.
In June, AstraZeneca along with Sinopharm,
Johnson & Johnson, Pfizer BioNTech secured
the Zambia Medicines Regulatory Authority
approval for their COVID-19 vaccines to be
administered to citizens in Zambia.
In January, AstraZeneca and BenevolentAI
entered into a collaboration to advance its
drug development portfolio with novel AIgenerated chronic kidney disease target.
In August, AstraZeneca's Forxiga sodiumglucose cotransporter 2 inhibitor secured
approval in the European Union to treat
chronic kidney disease in adults.
In September, AstraZeneca entered into a
option to acquire remaining equity in Caelum
Page 10
AstraZeneca PLC
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Regulatory Approval
2021 Contracts/Agreements
2021 Contracts/Agreements
2021 Divestiture
2021 Contracts/Agreements
2021 Asset Disposal
2021 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Biosciences for US$ 500 million.
In June, the company and Akoya Biosciences
entered into a collaboration for spatial
biomarker analysis in immuno-oncology drug
development.
In May, AstraZeneca and Biocartis Group NV
entered into an agreement to expand
availability of Idylla EGFR biomarker testing
among patients with lung cancer.
In April, AstraZeneca has entered into a
collaboration agreement with Massachusetts
General Hospital to create digital health
solutions that address today’s most urgent
healthcare challenges.
In February, AstraZeneca and University
College London entered into a partnership to
focus on the development of new cancer
treatments.
In February, AstraZeneca entered into a
partnership with IDT Biologika to accelerate,
increase COVID-19 vaccine manufacturing in
Europe.
In November, AstraZeneca and Sinovac
Biotech received approval from The Drug
Control Authority for Covid-19 vaccines.
In September, AstraZeneca entered into a
partnership with Oncoshot to better streamline
the recruitment process for cancer clinical
trials.
In March, AstraZeneca and Aptamer Group
entered into a partnership to evaluate the
potential of using Optimer-based strategies.
In January, AstraZeneca divested its heart
failure and hypertension brand, Atacand to
Cheplapharm Arzneimittel GmbH.
In May, AstraZeneca and Alchemab
Therapeutics entered into a collaboration to
accelerate prostate cancer research.
In May, AstraZeneca sold the rights to
trademarks of diabetes drug Dapagliflozin
under brands Oxra, Oxramet and Oxraduo in
India to Sun Pharma.
In August, AstraZeneca's Forxiga, a sodiumglucose cotransporter 2 inhibitor, received
approval in Japan for the treatment of chronic
kidney disease in adults with and without
type-2 diabetes.
Page 11
AstraZeneca PLC
2021 Regulatory Approval
2021 Contracts/Agreements
2021 Regulatory Approval
2021 Regulatory Approval
2021 Contracts/Agreements
2021 Regulatory Approval
2021 Contracts/Agreements
2021 Regulatory Approval
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
In July, AstraZeneca secured approval from
European Commission for proposed
acquisition of Alexion Pharmaceuticals for
approximately US$39 billion.
In January, AstraZeneca along with Amgen,
and Bristol Myers Squibb entered into a
collaboration with GRAIL Inc to evaluate
GRAIL’s methylation-based technology for
the detection of minimal residual disease.
In July, AstraZeneca and Sputnik V secured
approval from Russia for clinical trials of a
combination of both the coronavirus vaccine.
In June, AstraZeneca and MSD received
conditional approval for Koselugo
(selumetinib) from the European Commission
for the treatment of symptomatic, inoperable
plexiform neurofibromas (PN) in paediatric
patients with neurofibromatosis type 1 (NF1).
In January, AstraZeneca entered into a
collaboration with Care Access Research to
accelerate a clinical trial in the US for
AZD7442 for the potential prevention of
COVID-19.
In April, AstraZeneca secured approval from
US Federal Trade Commission to acquire
Alexion Pharmaceuticals, Inc.
In January, AstraZeneca entered into a
research collaboration with Recombinetics to
inform the knowledge base of
Neurofibromatosis Type 1.
In January, AstraZeneca and Sinovac Biotech
received approval from the Brazilian health
regulator Anvisa for the emergency use of
their COVID-19 vaccines.
In January, AstraZeneca entered into a
collaboration agreement with Biocartis Group
for the development of Idylla based molecular
tests in support of AstraZeneca’s
pharmaceutical products.
In October, AstraZeneca entered into an
agreement to acquire MSC-1, an anti-LIF
antibody from Northern Biologics.
In November, AstraZeneca and OM Pharma
entered into a strategic collaboration
agreement to distribute the immunological
therapy Broncho-Vaxom to treat respiratory
tract infections in China.
Page 12
AstraZeneca PLC
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 New Products/Services
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
In August, AstraZeneca signed an agreement
with Redx Pharma to license a porcupine
inhibitor, RXC006, for fibrotic diseases.
In September, AstraZeneca along with the
University of Queensland, the University of
Oxford, and CSL signed a US$1.2 billion
worth supply and production agreement with
the Government of Australia to offer a free
COVID-19 vaccine to Australian citizens.
In October, AstraZeneca secured a US$286.9
million contract from the US Army to supply
200 doses of the coronavirus vaccine
candidate AZD1222.
In May, AstraZeneca received US$1 billion
from the U.S. Health Department’s
Biomedical Advanced Research and
Development Authority (BARDA) for the
development, production and delivery of a
vaccine against the SARS-CoV-2, the virus
that causes coronavirus disease (COVID-19).
In August, AstraZeneca entered into a
partnership with Cytena GmbH and its
affiliate cytena Bioprocess Solutions Ltd to
develop plate-based microbioreactors for cell
line development workflows.
In October, AstraZeneca’s subsidiary
AstraZeneca Pharma India launched
Acalabrutinib 100 mg capsules for the
treatment of various types of blood cancers,
under the brand name Calquence.
In May, AstraZeneca and ArcherDX entered
into a collaboration to develop personalized
cancer monitoring assays to treat early-stage
non-small cell lung cancer therapies.
In September, AstraZeneca and Samsung
Biologics signed a US$330 million long-term
supply agreement to produce therapies.
In September, AstraZeneca entered into an
agreement to acquire a preclinical oral PCSK9
inhibitor programme from Dogma
Therapeutics.
In April, the company collaborated with
Novacyt S.A., GSK and the University of
Cambridge to boost testing for COVID-19.
In October, AstraZeneca secured a US$286.9
million contract to supply 200 doses of the
coronavirus vaccine candidate AZD1222 to
Page 13
AstraZeneca PLC
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Regulatory Approval
2020 Divestiture
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
the US Army.
In August, AstraZeneca entered into a
collaboration with RenalytixAI to develop and
launch medicine strategies for cardiovascular,
renal and metabolic diseases.
In September, AstraZeneca along with
Thermo Fisher Scientific and the University of
Nebraska Medical Center to improve the
clinical needs in biomarker discovery and
characterization.
In November, AstraZeneca and Merck’s
Lynparza secured approval from the European
Commission for prostate cancer and ovarian
cancer treatments in the European Union.
In April, AstraZeneca completed the
divestment of Movantik to RedHill
Biopharma.
In March, the company signed an agreement
to sell global commercial rights to Inderal,
Tenormin, Tenoretic, Zestril and Zestoretic to
Atnahs Pharma.
In September, AstraZeneca entered into an
agreement with the Government of Canada to
supply up to 20 million doses of its COVID19 vaccine candidate.
In June, AstraZeneca and Emergent
BioSolutions entered into a US$87 million
agreement for Covid-19 vaccine candidate
developed by the Oxford University.
In July, AstraZeneca entered into a
collaboration with IQVIA for the development
of a potential new vaccine for COVID-19.
In June, AstraZeneca and Accent Therapeutics
entered into a collaboration to develop
targeting RNA-modifying proteins to treat
people with cancer.
In April, the company signed an agreement
with the University of Oxford to develop and
distribute the Covid-19 vaccine candidate.
In January, the company and MiNA
Therapeutics entered into a research
collaboration for the discovery and
development of saRNA therapeutics to treat
patients with metabolic diseases.
In March, AstraZeneca and Schrodinger
announced to expand their collaboration to
extend computational modeling solutions to
Page 14
AstraZeneca PLC
2020 Contracts/Agreements
2020 Regulatory Approval
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
biologics.
In June, AstraZeneca and Amoy Diagnostics
entered into a partnership for the growth of
molecular diagnostic testing for lung cancer
patients in China.
In November, AstraZeneca received approval
for its Calquence (acalabrutinib) from the
European Commission for the treatment of
adult patients with chronic lymphocytic
leukaemia.
In June, AstraZeneca and the Vanderbilt
University (VU) entered into an agreement to
advance two coronavirus-neutralizing
antibodies discovered by the Vanderbilt
Vaccine Center into clinical development as a
potential combination therapy for the
prevention of COVID-19.
In February, AstraZeneca and Cellink Global
announced to renew their agreement to use
Cellinks’ 3D bioprinting and associated
technology for drug discovery.
In November, AstraZeneca and Fusion
Pharmaceuticals entered into a collaboration
to develop and commercialize next-generation
alpha-emitting radiopharmaceuticals for the
treatment of cancer.
In March, AstraZeneca partnered with
BrightInsight Inc to build its digital health
solutions.
In September, AstraZeneca along with Eisai,
Johnson & Johnson, Boehringer Ingelheim,
Merck KGaA, Pfizer, Sanofi, Roche, Bayer,
Bristol-Myers Squibb, bioMerieux, Novartis,
Gilead Sciences, Merck & Co, Eli Lilly, and
GlaxoSmithKline entered into a partnership to
prioritize the safety, science and accessibility
of the potential vaccines to help fight against
corona pandemic.
In March, AstraZeneca entered into an
agreement with Silence Therapeutics to
develop and commercialize small interfering
RNA therapeutics to treat cardiovascular,
renal, metabolic and respiratory diseases.
In February, AstraZeneca announced to invest
US$200 million in local manufacturing
capability at North Ryde, Sydney, Australia.
In December, AstraZeneca and Genome
Page 15
AstraZeneca PLC
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
2020 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Biologics UG entered into a research
collaboration to drive cardiac regeneration and
recovery in heart failure, myocardial
infarction, and Cardiotoxicity.
In July, AstraZeneca and ProteinQure entered
into a collaboration to accelerate the research
and development of peptide therapeutics.
In January, AstraZeneca and My Green Lab
entered into a collaboration to implement a
global scale green labs program.
In December, AstraZeneca along with RPharm, the Russian Direct Investment Fund,
and the Gamaleya National Center signed an
agreement for clinical research program to
asses the combined use of Sputnik V vaccine
developed by the Gamaleya Center with
AZD1222 vaccine, developed by AstraZeneca
and the University of Oxford.
In July, AstraZeneca and Daiichi Sanky
collaborated to develop and commercialize
Daiichi Sankyo’s trophoblast cell-surface
antigen 2 (TROP2)-directed antibody-drug
conjugate (ADC), DS-1062, to treat multiple
tumors.
In August, AstraZeneca and Eko entered into
a global collaboration to accelerate the
development of digital health tools to screen
cardiovascular diseases.
In June, AstraZeneca and Daiichi Sankyo
announced an agreement to supply novel
corona virus vaccine in Japan being developed
by AstraZeneca and Oxford University.
In June, AstraZeneca entered into a supply
agreement with Symbiosis Pharmaceutical
Services for sterile manufacture of the
COVID-19 recombinant adenovirus vaccine,
AZD1222 for AstraZeneca sponsored clinical
trials.
In August, AstraZeneca and the European
Union entered into an agreement where
European Union agreed to buy at least 300
million doses of AstraZeneca's potential
COVID-19 vaccine.
In April, the company partnered with Vidscrip
to bring COVID-19-specific messaging to all
US physicians, at no cost, amidst COVID-19
pandemic.
Page 16
AstraZeneca PLC
2020 Contracts/Agreements
In May, AstraZeneca entered into a
partnership with Oxford Biomedica to
enhance manufacturing capacity to produce
one billion doses of COVID-19 vaccine.
2020 Contracts/Agreements
In December, AstraZeneca and moksha8
Mexico signed an agreement to promote and
distribute Duaklir and Eklira in Mexican
Territory.
2020 Financing Agreements
In February, the company invested US$3
million in Starpharma, after the successful
trail in the phase 1 clinical trial of AZD0466
(DEP Bcl2/xL conjugate).
2020 Contracts/Agreements
In December, AstraZeneca agreed to acquire
Alexion.
2020 Corporate Changes/Expansions In June, AstraZeneca in partnership with
Gendius launched Health Innovation Hub in
the Gulf Cooperation Council (GCC).
2020 Contracts/Agreements
In March, AstraZeneca entered into a
multiyear license agreement with ImaginAb to
use CD8 ImmunoPET in its North American
and European immunotherapy clinical trials.
2020 Contracts/Agreements
In August, AstraZeneca along with Mexico
and Argentina entered into a national supply
agreement, in which the two countries agreed
to produce COVID-19 vaccine doses for the
company.
2020 Contracts/Agreements
In October, AstraZeneca and Arcus
Biosciences entered into a partnership to
evaluate the combination therapy to treat
advanced non-small cell lung cancer.
2019 Plans/Strategy
In June, AstraZeneca announced its plans to
invest US$630 million into Korea’s biotech
and healthcare sector.
2019 Financing Agreements
In September, AstraZeneca announced to
invest in SP Scientific LyoConstellation
system to research and develop small scale
GMP production.
2019 Contracts/Agreements
In April, AstraZeneca and BenevolentAI
collaborated for the usage of artificial
intelligence and machine learning for the
discovery and development of new treatments
for chronic kidney disease (CKD) and
idiopathic pulmonary fibrosis (IPF).
2019 Contracts/Agreements
In November, AstraZeneca entered into a codevelopment partnership with Novoheart to
develop human-specific in vitro, functional
model of heart failure with preserved ejection
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 17
AstraZeneca PLC
fraction.
2019 Contracts/Agreements
In January, the company and Luye Pharma
signed an agreement for the promotion of the
company's Xuezhikang capsules in the
mainland China.
2019 Acquisitions/Mergers/Takeovers In August, AstraZeneca agreed to acquire US
Food and Drug Administration Priority
Review Voucher for US$95 million from
Swedish Orphan Biovitrum AB.
2019 Contracts/Agreements
In February, the company entered into a
partnership agreement with NASSCOM to
expand AstraZeneca’s healthcare and
innovation in India.
2019 Contracts/Agreements
In May, AstraZeneca and Sensei
Biotherapeutics entered into a clinical trial
collaboration to evaluate the combination of
Sensei’s SNS-301 with IMFINZI to treat
multiple solid tumor.
2019 Contracts/Agreements
In December, the company collaborated with
Gatehouse Bio to accelerate new drug
discovery identification of new targets for
respiratory and cardiovascular diseases.
2019 Contracts/Agreements
In July, AstraZeneca and BioCardia entered
into a development agreement for BioCardia’s
Helix biotherapeutic delivery catheter system.
2019 Contracts/Agreements
In September, AstraZeneca and Schrodinger
entered into a collaboration to deploy
advanced computing platform to help
accelerate drug discovery efforts.
2019 Contracts/Agreements
In February, the Group signed a clinical
partnership with NeoTX to analyze ANYARA
in combination with IMFINZI (durvalumab).
2019 Contracts/Agreements
In March, AstraZeneca and Daiichi Sankyo
entered into a collaboration for the
development of novel HER2-targeting
antibody-drug conjugate, trastuzumab
deruxtecan.
2019 Corporate Awards
In December, the company was recognized
with the Best Place To Work certification in
Lebanon, Jordan and for the first year in Iraq.
2019 Contracts/Agreements
In January, the company signed an agreement
with Aptamer Group to develop the next
generation of drug delivery vehicles, called
Aptamer Drug Conjugates.
2019 Contracts/Agreements
In November, the company and Omron
Healthcare has entered into an agreement to
research and develop disease management
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 18
AstraZeneca PLC
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Divestiture
2019 Stake Sale
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
2019 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
solutions for patients.
In November, the company signed a
collaboration agreement with PCI Biotech to
upgrade the delivery of AstraZeneca’s nucleic
acid therapeutic compounds.
In April, AstraZeneca and Merck expanded its
companion diagnostic collaboration with
Myriad Genetics to use Myriad’s
BRACAnalysis CDx to identify men with a
type of prostate cancer in a Phase III trial.
In May, AstraZeneca partnered with Bob
Harper, a health and fitness expert, to expand
the Survivors Have Heart movement.
In December, the company divested the
commercial rights to Arimidex (anastrozole)
and Casodex (bicalutamide) to Juvise
Pharmaceuticals for a value of US$181
million.
In September, the company agreed to sell its
global commercial rights to Losec for US$243
million.
In March, AstraZeneca and Seres signed a
research collaboration to focus on advancing
mechanistic understanding of the microbiome
therapeutics to augment immuno-oncology
treatment for cancer.
In October, AstraZeneca entered into an
agreement to sell Seroquel medicine rights in
Russia and Europe to Cheplapharm
Arzneimittel for US$239 million.
In October, AstraZeneca entered into an
agreement with Takeda, ImaginAb, and Pfizer
for the development of its CD8 ImmunoPET
technology.
In December, the company signed an
agreement to acquire Novexel, a France-based
infection research company.
In June, the company signed an agreement
with Starpharma to progress the development
of a Dendrimer Enhanced Product version one
of its major marketed oncology medicines.
In December, AstraZeneca and DeepMatter
Group entered into a partnership to improve
the productivity of chemical synthesis
processes using digital technologies.
In September, the company announced to
licenses Poly ADP-Ribose Polymerase
Page 19
AstraZeneca PLC
2018 Contracts/Agreements
2018 Commercial Operation
2018 Regulatory Approval
2018 Contracts/Agreements
2018 Regulatory Approval
2018 Regulatory Approval
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
inhibitors to Theragnostics to develop novel
radiopharmaceuticals for a broad range of
cancers.
In June, AstraZeneca and the University of
Cambridge partnered with LUMICKS to form
the Center of Excellence for Dynamic SingleMolecule Analysis to advance the drug
discovery and biology research.
In September, Amgen and AstraZeneca
secured the breakthrough therapy status for
tezepelumab, which treats severe asthma.
In December, AstraZeneca and FibroGen
China secured the marketing authorization
from the National Medical Products
Administration to treat anaemia in chronic
kidney disease patients.
In January, the company partnered with
TissUse GmbH to utilize Microphysiological
Systems in the drug development process.
In January, AstraZeneca and Merck secured
the US FDA approval for its LYNPARZA
(olaparib), to use deleterious or suspected
deleterious germline BRCA-mutated
(gBRCAm) disease patients.
In November, the company secured the US
FDA grant the Orphan Drug Designation for
Fasenra, which treats Eosinophilic
Granulomatosis with Polyangiitis.
In October, the company signed a US$922
million licence deal to sell rights for Nexium
and Vimovo to Grunenthal Group.
In June, AstraZeneca collaborated with
Lumicks to introduce C-Trap optical tweezers
fluorescence microscope.
In January, AstraZeneca, in collaboration with
Regeneron, Alnylam Pharmaceuticals, Biogen
and Pfizer formed a major pre-competitive
consortium for funding the generation of
genetic exome sequence data.
In September, the company and Biothera
Pharmaceuticals entered into an agreement to
evaluate the combination of Imprime PGG
and durvalumab (IMFINZI) to decrease tumor
volume in patients prior to surgical resection.
In February, AstraZeneca secured an approval
from the US FDA for Imfinzi to treat patients
with unresectable Stage III non-small cell lung
Page 20
AstraZeneca PLC
cancer (NSCLC).
2018 Contracts/Agreements
In July, AstraZeneca entered into an
agreement to sell the European commercial
rights for its Atacand drug to Cheplapharm
Arzneimittel for US$200million.
2018 Contracts/Agreements
In October, AstraZeneca entered into an
agreement with Innate Pharma to develop the
treatments for cancer.
2018 Contracts/Agreements
In May, the company entered into an
agreement with Luye Pharma for the sale and
licence of the rights to Seroquel and Seroquel
XR in the UK, China and other international
markets.
2018 Contracts/Agreements
In July, the company collabrated with
Geisinger to enhance asthma care by
developing a suite of products which is
integrated into the electronic health record.
2018 Contracts/Agreements
In February, AstraZeneca and Bavarian
Nordic collaborated to investigate its targeted
immunotherapy candidate, CV301,and
company's PD-L1 inhibitor, durvalumab.
2018 Contracts/Agreements
In January, the company expanded research
collaboration agreement with Myriad
Genetics, Inc., under which Myriad will use
its myChoice HRD Plus test.
2018 Regulatory Approval
In August, AstraZeneca's Tagrisso
(osimertinib) secured the Japanese Ministry of
Health, Labour and Welfare (MHLW)
approval as the 1st-line treatment for
inoperable or recurrent epidermal growth
factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC) patients.
2018 Contracts/Agreements
In July, AstraZeneca and Immunomedics Inc,
entered into an agreement to evaluate and
develop treatment therapies for patients with
triple-negative breast cancer (TNBC) and
urothelial cancer (UC).
2018 Regulatory Approval
In September, the company's Lumoxiti
received approval from the US Food and Drug
Administration (FDA) to treat hairy cell
leukaemia.
2018 Corporate Changes/Expansions In February, the company's AstraZeneca
Pharma India launched an anti-diabetic
combination, once-daily therapy Xigduo XR
to treat adults with type 2 diabetes.
2018 Divestiture
In November, the company divested its US
rights to Synagis (palivizumab) to Swedish
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 21
AstraZeneca PLC
Orphan Biovitrum, worth US$1.6 billion.
2018 Contracts/Agreements
In January, the company and MedImmune
secured the European Commission approval
for its Fasenra (benralizumab) as an add-on
maintenance treatment in adult patients with
severe eosinophilic asthma.
2018 Contracts/Agreements
In January, AstraZeneca and X-Cheme
extended their partnership for global drug
research and technology transfer.
2018 Contracts/Agreements
In February, AstraZeneca and Charles River
collaborated to access the high-throughput
screening (HTS) and compound management
infrastructure of AstraZeneca.
2018 Contracts/Agreements
In January, AstraZeneca and Dong-A ST
entered into a joint research agreement to
develop new innovative immuno-oncology
drug candidates.
2018 Acquisitions/Mergers/Takeovers In April, the company agreed to acquire an
additional 5.7% stake in Circassia
Pharmaceuticals.
2018 Contracts/Agreements
In August, the company and MedPacto
entered into an agreement to evaluate the
safety and efficacy of vactosertib (TEW-7197)
with durvalumab to treat patients with
metastatic non-small cell lung cancer
(NSCLC).
2018 Contracts/Agreements
In December, the company and Guardant
Health entered into an agreement to develop
blood-based companion diagnostic (CDx)
tests to support the commercialization of its
oncology portfolio.
2018 Corporate Changes/Expansions In December, the company collaborated with
Cancer Research UK to open a functional
genomics centre for the discovery of new
medicines.
2018 Acquisitions/Mergers/Takeovers In November, AstraZeneca agreed to divest its
rights for Alvesco (ciclesonide), Omnaris and
Zetonna (ciclesonide) medicines to Covis
Pharma for US$371million.
2018 Regulatory Approval
In February, the company and Merck & Co
secured the US FDA's Orphan Drug
Designation for selumetinib, a MEK 1/2
inhibitor, to treat neurofibromatosis type 1
(NF1).
2018 Contracts/Agreements
In August, the company along with Maze
secured a construction contract for the
Cambridge Pharma HQ.
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 22
AstraZeneca PLC
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Regulatory Approval
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2018 Contracts/Agreements
2017 Contracts/Agreements
2017 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
In December, the company and Cancer
Research UK to open a new centre in the
Milner Research Labs in Cambridge.
In January, AstraZeneca and Merck secured
the Japanese Ministry of Health, Labour and
Welfare approval for its LYNPARZA
(olaparib), to treat patients with platinumsensitive relapsed ovarian cancer.
In August, AstraZeneca entered into a
collaboration agreement with Voluntis, in the
field of oncology.
In April, the company's cancer treatments
Moxetumomab Pasudotox and Lynparza
received US and European regulator approval.
In October, the company partnered with
Medicines Discovery Catapult to advance to
adopt Acoustic Mist Ionisation Mass
Spectrometry through drug discovery.
In April, AstraZeneca and Molecular Partners
collaborated for clinical study of MP0250
with osimertinib (Tagrisso) to treat patients
with EGFR-mutated Non-Small Cell Lung
Cancer (NSCLC) pre-treated with osimertinib.
In December, AstraZeneca and AVEO
Oncology signed an Immuno-Oncology
clinical collaboration for AstraZeneca's
IMFINZ and AVEO’s FOTIVDA in FirstLine HCC.
In February, AstraZeneca partnered with
Alibaba and Tencent to utilize AI and the
internet of things to provide smart healthcare
services in China.
In April, the company and Owlstone Medical
entered into a service agreement to provide
access to Breath Biopsy Services to identify
novel biomarkers in Asthma and COPD.
In February, AstraZeneca and Syndax signed a
clinical collaboration to evaluate the efficacy
of company's durvalumab, a human
monoclonal antibody.
In May, the company's Centre for Genomics
Research selected DNAnexus's secure cloudbased platform to analyze more than two
million genomes for drug discovery and
development.
In May, the company received accelerated
approval from the US Food and Drug
Page 23
AstraZeneca PLC
Administration for Imfinzi (durvalumab) to
treat the patients with advanced or metastatic
urothelial carcinoma.
2017 Contracts/Agreements
In June, the company signed an agreement
with Grunenthal to own the global rights to
Zomig outside Japan.
2017 Corporate Changes/Expansions In July, the company planned to expand its
Sydney facility by investing US$100 million.
2017 Contracts/Agreements
In May, AstraZeneca selected Biologics Inc to
act as a specialty pharmacy provider for
IMFINZITM (durvalumab) in the limited
distribution network.
2017 Contracts/Agreements
In July, AstraZeneca entered into a strategic
collaboration with Merck for the codevelopment and co-commercialization of
AstraZeneca's Lynparza for multiple cancer
types.
2017 New Product Approvals
In June, the company received a positive
Committee for Medicinal Products for Human
Use (CHMP) opinion for use of Faslodex in
1st-line hormone receptor-positive advanced
breast cancer.
2017 Regulatory Approval
In November, AstraZeneca received an
approval of Faslodex from the US Food and
Drug Administration (FDA) for the treatment
of metastatic breast cancer (MBC) in women
with disease progression after endocrine
therapy.
2017 Contracts/Agreements
In November, the company and CN Bio
Innovations signed a research collaboration
for validation of a new in vitro research tool.
2017 Product Recall
In May, the company recalled the physician
sample bottles of BRILINTA heart drug.
2017 Contracts/Agreements
In October, the company selected
AstraZeneca, to distribute CALQUENCE.
2017 Contracts/Agreements
In November, the company selected Biologics
Inc, for CALQUENCE to be in the limited
distribution network.
2017 Contracts/Agreements
In September, AstraZeneca and NewLink
Genetics signed a clinical collaboration
agreement to evaluate combination of
NewLink Genetics’ small molecule IDO
pathway inhibitor, indoximod, and
AstraZeneca’s anti-PD-L1 monoclonal
antibody,durvalumab.
2017 Contracts/Agreements
In January, Guardant Health signed a separate
agreements with Merck KGaA, AstraZeneca,
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 24
AstraZeneca PLC
2017 Contracts/Agreements
2017 Contracts/Agreements
2017 Regulatory Approval
2017 Contracts/Agreements
2017 Contracts/Agreements
2017 Regulatory Approval
2017 Contracts/Agreements
2017 New Product Approvals
2017 Contracts/Agreements
2017 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Darmstadt, Merck, and Pfizer to develop a
new 500-plus-gene liquid biopsy panel to
enhance clinical trials for the development of
cancer drugs.
In October, the company entered into an
agreement with Sawai Pharmaceutical Co.,
Ltd., to manufacture and market Zomig
Tablets 2.5 mg and Zomig Rapid Melt Tablets
2.5 mg, a migraine medication in Japan.
In June, Astrazenca along with National
Cancer Institute Eleven entered into
cooperative research and development
agreement with Eleven Biotherapeutics to
develop Vicinium in combination with
AstraZeneca's immune checkpoint inhibitor,
Imfinzi to treat non-muscle invasive bladder
cancer.
In October, AstraZeneca secured an approval
from the US FDA for its Bydureon BCise
injectable suspension to treat adults with type2 diabetes.
In August, AstraZeneca entered into an
agreement with Takeda Pharmaceutical to
jointly develop and commercialise
MEDI1341, an alpha-synuclein antibody to
treat Parkinson’s disease.
In October, AstraZeneca signed a
Development partnership with Roivant
Sciences for investigational drug in a new
therapeutic area that can reach patients.
In January, the company received the US
Food and Drug Administration approval for
Symbicort, for the treatment of asthma in
paediatric patients.
In August, the company along with
MedImmune signed a strategic collaboration
with Ethris to develop mRNA therapies for
respiratory diseases.
In August, the company received the U.S.
Food and Drug Administration approval to
olaparib tablets for maintenance treatment in
ovarian cancer.
In October, the company and Avara
Pharmaceutical signed an agreement to
acquire the Reims, France manufacturing and
distribution facility.
In May, Recordati signed an agreement to
Page 25
AstraZeneca PLC
acquire the company’s metoprolol-based
treatments in Europe for a value at
approximately US$300 million.
2017 Corporate Changes/Expansions In March, the company's subsidiary,
AstraZeneca India Private Ltd opened a new
facility in Chennai to expand its presence in
India.
2017 Contracts/Agreements
In September, the company, GSK, and
Labcyte partnered to develop acoustic mass
spectrometry.
2017 Contracts/Agreements
In November, the company and G1
Therapeutics signed a collaboration agreement
to evaluate AstraZeneca’s epidermal growth
factor receptor tyrosine kinase inhibitor
Tagrisso.
2017 Contracts/Agreements
In December, AstraZeneca signed a
partnership with Imperial College London to
perform research on biological drivers such as
asthma and COPD.
2017 Divestiture
In December, AstraZeneca sold its the NDAs
and U.S. rights to market ATACAND,
ATACAND HCT, ARIMIDEX, and
CASODEX to ANI Pharmaceuticals, for
US$46.5 million.
2017 Contracts/Agreements
In October, AstraZeneca received the US FDA
approval for its CALQUENCE
(acalabrutinib), a Bruton tyrosine kinase
(BTK) inhibitor.
2017 Contracts/Agreements
In June, the company signed an agreement
with Trovagene, which utilizes Trovera
ctDNA test and services in prospective
biomarker study.
2017 Contracts/Agreements
In August, the company entered into a
strategic collaboration with Champions
Oncology, Inc, to develop unique cohorts of
Patient-Derived Xenograft (PDX) models.
2017 Contracts/Agreements
In December, AstraZeneca and Chembio
Diagnostics collaborated for the development
of a novel POC diagnostic test to detect an
undisclosed biomarker.
2017 Contracts/Agreements
In November, the company signed a strategic
joint venture with the Chinese Future Industry
Investment Fund (FIIF) to establish a 50/50
stand-alone company in China for the
discovery, development and
commercialization of potential new medicines.
2017 Regulatory Approval
In November, AstraZeneca received the US
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 26
AstraZeneca PLC
2017 Contracts/Agreements
2017 Contracts/Agreements
2017 Contracts/Agreements
2017 New Product Approvals
2017 Regulatory Approval
2017 Contracts/Agreements
2017 Contracts/Agreements
2017 New Product Approvals
2017 Contracts/Agreements
2016 Asset Purchase
2016 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
FDA approval for its Calquence
(acalabrutinib) to treat mantle cell lymphoma
(MCL) in adult patients.
In November, the company entered into an
agreement with Aralez Pharmaceuticals
Trading, for beta-blocker medicine Toprol-XL
in the US.
In May, the company and Genomic Vision
collaborated for novel anti-cancer treatments
strategy in the area of targeting DNA damage
response (DDR).
In May, AstraZeneca entered into
collaboration with Pieris Pharmaceuticals for
the development of novel inhaled drugs based
on Anticalin to treat respiratory diseases.
In August, the company and Acerta Pharma
received the US Food and Drug
Administration approval for breakthrough
therapy designation for the treatment of
patients with mantle cell lymphoma.
In November, AstraZeneca received an
approval for its Fasenra product, which is an
add-on maintenance treatment of patients with
severe asthma aged 12 years and older from
the US Food and Drug Administration (FDA).
The company entered into a partnership with
uMotif, to improve patient data capture.
In June, the company selected ArisGlobal for
its cloud-based solution, LifeSphere SafetyRisk Management that provides
comprehensive set of data analytics for endto-end signal detection and risk management.
In July, the company's subsidiary MedImmune
announced that its partner Leo Pharm received
an approval from the European Commission
(EC) for its Kyntheum to treat moderate-tosevere plaque psoriasis.
In June, the company signed an agreement
with ArisGlobal for LifeSphere Risk
Management platform.
In October, AstraZeneca purchased a
manufacturing plant in Longmont, Coloroda,
the US from Amgen Inc for US$64.5 million.
In January, the company, GlaxoSmithKline,
Johnson & Johnson Innovation entered into
collaboration with technology transfer offices
of Imperial College London, UCL Business
Page 27
AstraZeneca PLC
2016 Regulatory Approval
2016 Regulatory Approval
2016 Contracts/Agreements
2016 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
and the University of Cambridge to create the
Apollo Therapeutics Fund for therapeutic
innovation.
In April, the company received an approval
from US Food and Drug Administration for its
Bevespi Aerosphere, for patients with COPD.
Also in March 2016, AstraZeneca and
MedImmune announced that FDA granted
Orphan Drug Designation for the
investigational anti-CD19 monoclonal
antibody, MEDI-551, for the treatment of
patients with neuromyelitis optica (NMO) as
well as neuromyelitis optica spectrum
disorders (NMOSD). In May 2016,
AstraZeneca completed the acquisition of the
core respiratory business of Takeda
Pharmaceutical Company Limited (Takeda).
In the following month, AstraZeneca
completed the licensing agreement with
Ironwood Pharmaceuticals for the exclusive
US rights to Zurampic® (lesinurad) and the
fixed-dose combination of lesinurad and
allopurinol for the treatment of hyperuricemia
associated with uncontrolled gout. Also in
June 2016, AstraZeneca entered into a
definitive agreement with Foundation
Medicine, Inc. (Foundation Medicine) to
develop a novel companion diagnostic assay
for Lynparza (olaparib) that can enable
physicians to identify those patients most
likely to benefit from the company’s poly
ADP-ribose polymerase (PARP) inhibitor. In
July 2016, AstraZeneca entered into an
agreement with LEO Pharma A/S for the
global licence to tralokinumab in skin
diseases. In the following month, AstraZeneca
and Eli Lilly and Company (Lilly) announced
that they received FDA Fast Track designation
for the development programme in
Alzheimer’s disease for AZD3293, an oral
beta secretase cleaving enzyme (BACE)
inhibitor currently in Phase III clinical trial.
In November, the company and Cytel to
implement a software interface for go/no-go
decision-making.
In May, the company, Antaros Medical, and
Sahlgrenska University Hospital collaborated
to develop new tools to treat chronic kidney
Page 28
AstraZeneca PLC
2016 Contracts/Agreements
2016 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
disease.
In January 2016, AstraZeneca and Incyte
Corporation announced a collaboration to
evaluate the efficacy and safety of Incyte’s
Janus-associated kinase (JAK) 1 inhibitor,
INCB39110, in combination with
AstraZeneca’s epidermal growth factor
receptor (EGFR) inhibitor, Tagrisso®
(osimertinib). In the following month,
AstraZeneca completed the transaction to
acquire a majority equity stake in Acerta
Pharma, a privately-owned biopharmaceutical
company based in the Netherlands and US.
Also in February 2016, AstraZeneca entered
into a licensing agreement with China Medical
System Holdings Ltd (CMS) for the
commercialisation rights in China to its
calcium channel blocker, Plendil (felodipine).
In March 2016, AstraZeneca entered into an
agreement with ProStrakan Group, a
subsidiary of Kyowa Hakko Kirin Co. Ltd.,
for the rights to Moventig (naloxegol), the
first once-daily, oral peripherally-acting muopioid receptor antagonist (PAMORA)
approved in Europe for the treatment of
opioid-induced constipation, in the EU,
Iceland, Norway, Switzerland and
Liechtenstein.
In August 2016, AstraZeneca entered into an
agreement with Pfizer Inc. to sell the
commercialization and development rights to
its late-stage small molecule antibiotics
business in most markets outside the US. In
the following month, AstraZeneca completed
the commercialization agreement with Aspen
Global Incorporated (AGI), part of the Aspen
Group, for rights to its global anesthetics
portfolio outside the US that covers seven
established medicines: Diprivan (general
anaesthesia), EMLA (topical anaesthetic) and
five local anaesthetics
(Xylocaine/Xylocard/Xyloproct, Marcaine,
Naropin, Carbocaine and Citanest). Also in
September 2016, AstraZeneca and the U.S.
President’s Emergency Plan for AIDS Relief
(PEPFAR) announced a $10 million five-year
global public-private partnership that will
expand access to HIV/AIDS and hypertension
services by offering them in an integrated
Page 29
AstraZeneca PLC
manner at existing PEPFAR-supported
HIV/AIDS sites, beginning in Kenya. In the
following month, AstraZeneca entered into an
agreement with Aralez Pharmaceuticals
Trading DAC, a subsidiary of Aralez
Pharmaceuticals Inc., for the rights to branded
and authorised generic Toprol-XL (metoprolol
succinate) in the US. Also in the same month,
AstraZeneca entered into an agreement with
Cilag GmbH International, an affiliate of
Johnson & Johnson, for the divestment of the
rights to Rhinocort Aqua outside the US.
2015 Contracts/Agreements
Also in April 2015, AstraZeneca entered into
a strategic immuno-oncology collaboration
with Celgene Corporation to develop PD-L1
inhibitor programme for patients with serious
blood cancers. AstraZeneca entered an
agreement with Abbott to develop companion
diagnostic tests for tralokinumab in severe
asthma, in May 2015. The company
announced its plans to invest $285 million in a
new facility for manufacturing of biological
medicines in Sodertalje, Sweden. In the same
month, AstraZeneca and Eli Lilly and
Company entered into clinical trial
collaboration on immuno-oncology
combination clinical trial in solid tumors. In
July 2015, the company entered into an
agreement with Tillotts Pharma, a part of the
Zeria Group, for the divestment of global
rights, outside the US, to Entocort
(budesonide), a gastroenterology medicine for
patients with mild to moderate Crohn's disease
and ulcerative colitis. AstraZeneca entered an
agreement with Kyowa Hakko Kirin for
commercialization of benralizumab in Japan.
Further AstraZeneca divested global rights to
Entocort outside the US to Tillotts Pharma.
The company entered into a definitive
agreement with Genzyme to divest Caprelsa.
2015 Contracts/Agreements
In June, AstraZeneca collaborated with the
University of Michigan to advance the
treatment of chronic kidney disease.
2015 Acquisitions/Mergers/Takeovers In December 2015, the company completed its
agreement with Perrigo Company plc for the
divestment of US rights to Entocort®
(budesonide), a gastroenterology medicine for
patients with mild to moderate Crohn’s
disease, an area of medicine outside
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 30
AstraZeneca PLC
2015 Spin-off
2015 Contracts/Agreements
2015 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
AstraZeneca’s strategic focus. Also in the
same month, AstraZeneca acquired all the
outstanding shares of ZS Pharma, a
biopharmaceutical company based in San
Mateo, California for $90 per share. Also in
December 2015, the company got approval
from FDA for the use of ZURAMPIC®
(lesinurad) 200mg tablets in combination with
a xanthine oxidase inhibitor (XOI) for the
treatment of hyperuricemia associated with
gout in patients who have not achieved target
serum uric acid (sUA) levels with an XOI
alone.
In February, Entasis Therapeutics Spunout
from the company.
In January 2015, MedImmune entered into a
licensing agreement with Omnis
Pharmaceuticals, a clinical stage
biotechnology company for oncolytic viruses
in immuno-oncology. AstraZeneca acquired
the rights to Actavis' branded respiratory
business in the US and Canada, in March
2015. The company and Daiichi Sankyo
entered into an agreement to jointly
commercialize Movantik in the US. Further in
the same month, AstraZeneca entered into
five-year research collaboration with the
Harvard Stem Cell Institute (HSCI) to adapt a
technique that creates human beta cells from
stem cells for new treatment for diabetes. In
April 2015, AstraZeneca and PatientsLikeMe
announced global research collaboration on
improving health outcomes for patients across
main therapy areas. In the same month,
AstraZeneca and Innate Pharma collaborated
to accelerate and broaden the development of
Innate Pharma proprietary anti-NKG2A
antibody, IPH2201, including in combination
with MEDI4736, an anti-PD-L1 immune
checkpoint inhibitor developed by
MedImmune.
AstraZeneca and Isis Pharmaceuticals entered
into strategic collaboration to discover and
develop antisense therapies for cardiovascular,
metabolic and renal diseases, in August 2015.
MedImmune and Mirati Therapeutics entered
into collaboration for genetic and epigenetic
drivers of cancer. In the same month,
AstraZeneca and Heptares Therapeutics
Page 31
AstraZeneca PLC
2015 Contracts/Agreements
2015 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
entered into an agreement to develop novel
immuno-oncology treatments. Medimmune
entered into a strategic cancer vaccine
collaboration and license agreement with
Inovio Pharmaceuticals. During the same
month, AstraZeneca and Peregrine
Pharmaceuticals announced to collaborate on
immuno-oncology combination clinical trial
In September 2015, AstraZeneca purchased
the US biologics manufacturing facility from
Amgen to support its growing pipeline. The
company entered into a collaboration
agreement with Valeant Pharmaceuticals
International, under which it would grant an
exclusive license for Valeant to develop and
commercialize brodalumab. Further in
September 2015, the company entered into an
agreement with Daiichi Sankyo for
development and commercialization of
FluMist in Japan. During the same month,
AstraZeneca announced to invest £11.5
million (approximately $19 million) in new
clinical oncology bioinformatics collaboration
with The University of Manchester. The
company added to its biologics manufacturing
capability in the US with the purchase of a
high-tech biologics bulk manufacturing
facility from Amgen.
In September, Starpharma Holdings Limited
signed a licensing agreement with the
company for the development and
commercialization of oncology compounds
using Starpharma's DEP drug delivery
technology.
AstraZeneca announced that the FDA issued a
Complete Response Letter (CRL) regarding
the NDA for the investigational fixed-dose
combination of saxagliptin and dapagliflozin
for the treatment of adult patients with type 2
diabetes, in October 2015. In the same month,
the company opened its new state-of-the-art
manufacturing and packaging facility in
Kaluga, Russia, dedicated to the local supply
of innovative medicines Further in October
2015, AstraZeneca and Eli Lilly and Company
announced an extension to their existing
immuno-oncology collaboration exploring
novel combination therapies for the treatment
of patients with solid tumors. In November
Page 32
AstraZeneca PLC
2014 Contracts/Agreements
2014 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
2015, FDA approved TAGRISSO (AZD9291)
80mg once-daily tablets for the treatment of
patients with metastatic epidermal growth
factor receptor (EGFR) T790M mutationpositive non-small cell lung cancer (NSCLC).
During the same month, AstraZeneca and
Sanofi announced a direct exchange of
210,000 compounds from their respective
proprietary compound libraries. The company
announced three new partnerships that would
deliver industry-leading technologies to drive
the AstraZeneca MRC UK Centre for Lead
Discovery in the search for novel small
molecule medicines.
The company formed a collaboration with
gene sequencing company, Illumina, to
develop its next generation sequencing (NGS)
platform for companion diagnostic tests
applicable across AstraZeneca's oncology
portfolio, in 2014. In the same year,
AstraZeneca and Eli Lilly and Company
entered into an agreement to jointly develop
and commercialize AZD3293, an oral beta
secretase cleaving enzyme (BACE) inhibitor
currently in development as a potential
treatment for Alzheimer's disease. The FDA
granted marketing approval for Movantik
(naloxegol) tablets C-II as the first once-daily
oral peripherally-acting mu-opioid receptor
antagonist (PAMORA) medication for the
treatment of opioid-induced constipation in
adult patients with chronic, non-cancer pain.
AstraZeneca and Pharmacyclics entered into
clinical trial collaborations to evaluate novel
combination therapies targeting solid tumours
and a number of haematological cancers, in
2014. AstraZeneca, Pharmacyclics and
Janssen entered into collaboration on immunooncology combination trials with Imbruvica
for haematological cancers. Further in the
same year, MedImmune acquired Definiens.
In 2014, Moventig was approved in the EU for
opioid-induced constipation. In the same year,
Lynparza was approved by the EU and the
FDA for the treatment of advanced ovarian
cancer in patients with germline BRCAmutations.
In the second quarter of 2014, the
AstraZeneca's board rejected Pfizer's revised
Page 33
AstraZeneca PLC
2014 Contracts/Agreements
2014 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
non-binding proposal comprising £21.57
(approximately $34) in cash (40%) and 1.845
Pfizer shares (60%) per AstraZeneca share,
representing a value of £53.50 (approximately
$84) per AstraZeneca share. The FDA
approved AstraZeneca's Epanova for the
treatment of adults with severe
hypertriglyceridaemia in 2014. In the second
quarter, it designated AstraZeneca's novel
investigational drug, AZD0914, as a qualified
infectious disease product (QIDP) and
awarded its development program with 'Fast
Track' status for the treatment of
uncomplicated gonorrhoea, which is
increasingly resistant to existing antibiotics
and poses a serious global public health threat.
In the third quarter of 2014, MedImmune
entered into a clinical trial collaboration with
Advaxis, a US-based developer of cancer
immunotherapies, for evaluating the safety
and efficacy of MedImmune's investigational
anti-PD-L1 immune checkpoint inhibitor,
MEDI4736, in combination with Advaxis'
lead cancer immunotherapy vaccine, ADXSHPV, as a treatment for patients with
advanced, recurrent or refractory human
papillomavirus (HPV)-associated cervical
cancer and HPV-associated head and neck
cancer.
In May, AstraZeneca and Tianjin Medical
University entered into a research
collaboration to focus on exploring novel
targets against cardiac fibrosis in China.
Further in 2014, AstraZeneca entered into a
collaboration with Netherlands-based Qiagen
to develop a non-invasive diagnostic test to
identify non-small cell lung cancer (NSCLC)
patients who are suitable for treatment with
IRESSA. The company entered into a
collaboration agreement with Roche to
develop a plasma-based companion diagnostic
test to support AZD9291, AstraZeneca's
investigational compound in clinical
development for NSCLC. The company also
signed a clinical study collaboration
agreement with Kyowa Hakko Kirin for a
Phase I/Ib immuno-oncology study to evaluate
the safety and efficacy of two separate
combinations of three investigational
Page 34
AstraZeneca PLC
compounds in multiple solid tumours.
AstraZeneca entered an agreement to transfer
to the company the rights to respiratory
franchise of Almirall, a Spain-based
pharmaceutical company, for an initial
consideration of $875 million on completion,
and up to $1.22 billion in development, launch
and sales-related milestones. AstraZeneca also
agreed to make various sales-related
payments.
2014 Acquisitions/Mergers/Takeovers AstraZeneca acquired BMS' interests in their
global diabetes alliance for $2.7 billion in the
first quarter of 2014. In the same quarter, the
FDA granted US marketing approval for
AstraZeneca's orphan drug, Myalept
(metreleptin for injection), which is indicated
as an adjunct to diet as replacement therapy
for the treatment of complications of leptin
deficiency in patients with congenital or
acquired generalized lipodystrophy. The FDA
approved the Bydureon Pen (exenatide
extended-release for injectable suspension) for
once-weekly treatment of adults with type 2
diabetes in 2014. Further in the same quarter,
Japan's Ministry of Health, Labour and
Welfare (MHLW) approved AstraZeneca's
Forxiga as a once-daily oral treatment for type
2 diabetes. AstraZeneca completed the
purchase of Sumitomo Chemical's remaining
shares in AstraZeneca K.K for approximately
$102 million. The deal gave AstraZeneca
control of the entire shareholding of
AstraZeneca K.K.
2014 Contracts/Agreements
In 2014, MedImmune entered into an
oncology research collaboration and licensing
agreement with Immunocore, a UK-based
privately-held biotechnology company, under
which both companies would research and
develop novel cancer therapies using
Immunocore's immune mobilizing
monoclonal T-cell receptor against cancer
(ImmTAC) technology. The FDA granted
approval for Farxiga (dapagliflozin) for
treatment of type 2 diabetes in adults; and the
EC granted European marketing authorisation
for Xigduo (dapagliflozin and metformin
hydrochloride in 5mg/850mg and
5mg/1000mg tablets) for the treatment of type
2 diabetes. Pfizer launched first of its
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 35
AstraZeneca PLC
unsuccessful attempts to acquire AstraZeneca
in 2014. Pfizer made a preliminary and
conditional proposal regarding a possible offer
for AstraZeneca. The proposal comprised
£13.98 (approximately $22) in cash (30%) and
1.758 Pfizer shares (70%) per AstraZeneca
share, representing a value of £46.61
(approximately $73) per AstraZeneca share.
2013 Contracts/Agreements
In July, AstraZeneca and FibroGen entered
into a collaboration agreement for the
development and commercialization of
roxadustat for the treatment of anemia.
2013 Acquisitions/Mergers/Takeovers MedImmune acquired AlphaCore Pharma, a
Michigan-based biotechnology company
focused on the development of ACP-501, a
recombinant human lecithin-cholesterol
acyltransferase (LCAT) enzyme, in 2013; and
Amplimmune, a US-based privately held
biologics company focused on developing
novel therapeutics in cancer immunology; and
Spirogen, a privately-held biotech company
focused on antibody-drug conjugate
technology for use in oncology, in 2013.
AstraZeneca acquired Pearl Therapeutics, a
privately-held company based in California,
focused on the development of inhaled smallmolecule therapeutics for respiratory disease,
for approximately $1.15 billion in 2013;
Omthera Pharmaceuticals, a US-based
specialty pharmaceutical company, in 2013.
Also in the same year, AstraZeneca entered
into an agreement with Janssen
Pharmaceuticals K. K. in Japan to co-promote
abiraterone acetate, an innovative oral therapy
for the treatment of patients with prostate
cancer. The FDA accepted the company's
NDA for naloxegol in 2013. In the same year,
the EC granted approval for AstraZeneca's
Fluenz Tetra for the prevention of seasonal
influenza in children.
2012 Contracts/Agreements
In April, AstraZeneca entered into a
collaboration agreement with the Medicines
Company for the co-promotion of Brilinta
(ticagrelor) in the US.
2012 Regulatory Approval
In 2012, the EC granted marketing
authorisation for the company's Caprelsa
(vandetanib) for the treatment of aggressive
and symptomatic medullary thyroid cancer
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 36
AstraZeneca PLC
2012 Contracts/Agreements
2012 Contracts/Agreements
2011 Contracts/Agreements
Published: 24 Oct 2023
Extracted: 29 Oct 2023
(MTC) in patients with unresectable locally
advanced or metastatic disease. MedImmune
obtained the FDA approval for FluMist
Quadrivalent (Influenza Vaccine Live,
Intranasal) in the prevention of influenza.
FluMist Quadrivalent became the first fourstrain influenza vaccine approved by the FDA.
During 2012, AstraZeneca and Amgen
announced to jointly develop and
commercialize five monoclonal antibodies
from Amgen's clinical inflammation portfolio:
AMG 139, AMG 157, AMG 181, AMG 557
and brodalumab (AMG 827). AstraZeneca
acquired Ardea Biosciences, a US-based
developer of small molecule therapeutics, for
approximately $1.26 billion; and a portfolio of
neuroscience assets from Link Medicine
Corporation, a US-based biotechnology
company. AstraZeneca sold assets of its
subsidiary Aptium Oncology, a US-based
provider of oncology consulting services.
AstraZeneca out-licensed to Pfizer the OTC
rights to Nexium (esomeprazole magnesium),
a prescription drug approved to treat the
symptoms of gastroesophageal reflux disease
(GERD). AstraZeneca and BMS received EC
approval for Forxiga (dapagliflozin) tablets for
the treatment of type 2 diabetes in the
European Union (EU). AstraZeneca and Isis
Pharmaceuticals forged an alliance for the
discovery and development of novel
generation antisense therapeutics against five
cancer targets.
In June, Astellas entered into a collaboration
agreement with DNDi, on new drug discovery
research for the treatment of neglected tropical
diseases.
In October, the company and Pharmaron
signed a partnership to support their global
Innovative Medicines Units.
In 2011, both the companies extended their
co-promotion agreement to include
denosumab for the treatment of bone disorders
stemming from bone metastasis in Japan.
Further in the same year, AstraZeneca sold
Astra Tech, a provider of dental implants, and
medical devices for use primarily in urology
and surgery, to DENTSPLY International for
approximately $1.8 billion in cash.
Page 37
AstraZeneca PLC
2011 Contracts/Agreements
2011 Contracts/Agreements
2010 Contracts/Agreements
2010 Contracts/Agreements
2010 Contracts/Agreements
2010 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
AstraZeneca's Nexium received regulatory
approval in Japan for the treatment of acidrelated conditions including non-erosive
reflux disease (NERD), reflux esophagitis, and
peptic ulcer disease (PUD). Nexium also
received regulatory approval for prevention of
recurrence of gastric ulcer and duodenal ulcer
in patients treated with non-steroidal antiinflammatory drugs (NSAIDs). AstraZeneca
acquired Guangdong BeiKang Pharmaceutical
Company, a China-based privately-owned
generics manufacturing company.
In November, the company and Galderma
Pharma partnered to develop treatments for
dermatological conditions.
Neoprobe in-licensed the worldwide exclusive
rights from the company to the late-stage
radiopharmaceutical imaging candidate,
AZD4694, for aiding the diagnosis of
Alzheimer's disease (AD).
In May, the company entered into a
collaboration agreement with Targacept, Inc.,
for expanding the TC-5619 development
program.
In May, the company entered into a research
collaboration agreement with TB Alliance, to
fight tuberculosis.
In January, the company entered into a
research collaboration agreement with
CrystalGenomics, to discover and develop a
novel anti-infective.
During 2010, AstraZeneca's blockbuster
Crestor franchise received further boost as the
FDA approved the drug to reduce the risk of
stroke, heart attack and arterial
revascularization procedures in individuals
without clinically evident coronary heart
disease but with an increased risk of
cardiovascular disease (CVD) based on age
(men 50 and women 60), high-sensitivity Creactive protein (hsCRP) 2 mg/L, and the
presence of at least one additional CVD risk
factor, such as hypertension, low HDL-C,
smoking, or a family history of premature
coronary heart disease. Crestor received
marketing approval in 19 countries within the
EU in 2010 for the prevention of major
cardiovascular events in patients who are at
Page 38
AstraZeneca PLC
2009 Contracts/Agreements
2009 Contracts/Agreements
2009 Contracts/Agreements
2009 Contracts/Agreements
2009 Regulatory Approval
Published: 24 Oct 2023
Extracted: 29 Oct 2023
high risk of having a first cardiovascular
event. The EC granted marketing
authorization to AstraZeneca's Brilique
(ticagrelor tablets) for the prevention of
atherothrombotic events in adult patients with
Acute Coronary Syndromes (ACS).
AstraZeneca enhanced its infection therapy
pipeline in 2010 through the acquisition of
Novexel for $350 million and also additional
milestone payments of $75 million to Novexel
shareholders. The company signed an
agreement with Daiichi Sankyo for the copromotion and supply of Nexium in Japan in
2010.
In August, the company entered into a
definitive collaboration agreement with Forest
Laboratories, to co-develop and
commercialize ceftaroline in the United
States, Canada and Japan.
In February, the company signed an
agreement with Cellartis, to develop drug
safety testing using stem cells.
In August, the company entered into a drug
discovery and development agreement with
PsychoGenics Inc.
In May, Jubilant entered into a research
collaboration agreement with Jubilant, to
provide new preclinical drug candidates.
During 2009, the FDA granted US marketing
approvals for AstraZeneca's Symbicort
(budesonide/formoterol fumarate dihydrate)
160/4.5 mcg for the twice daily maintenance
treatment of airflow obstruction in patients
with chronic obstructive pulmonary disease
(COPD), including chronic bronchitis and
emphysema; Onglyza (saxagliptin) for the
treatment of type 2 diabetes mellitus in adults;
Seroquel as monotherapy and for the acute
treatment of manic episodes associated with
bipolar I disorder in children and adolescents
(10-17 years of age), both as monotherapy and
as an adjunct to lithium or divalproex; and for
Seroquel XR as adjunctive (add-on) treatment
to antidepressants in adults with major
depressive disorder. AstraZeneca received the
European Commission's (EC) marketing
authorisation for Iressa, an oral anti-cancer
drug, for the treatment of adults with locally
Page 39
AstraZeneca PLC
advanced or metastatic non-small cell lung
cancer (NSCLC) with activating mutations of
EGFR-TK (epidermal growth factor receptortyrosine kinase) across all lines of therapy.
2009 Contracts/Agreements
In June, the company signed a new multiproject research agreement with Cenix
BioScience GmbH.
2007 Acquisitions/Mergers/Takeovers During the second quarter of 2007, the FDA
approved the company's Seroquel XR
(quetiapine fumarate), a once-daily medicine
for the treatment of schizophrenia in adult
patients. AstraZeneca completed the $15.6billion acquisition of US-based biotech major
MedImmune in mid-2007. As a result of the
merger, MedImmune became the whollyowned subsidiary of AstraZeneca. The
addition of MedImmune significantly
enhanced AstraZeneca's biologic product and
pipeline portfolios. During the last quarter of
2007, the company's Seroquel XR received
FDA approval for maintenance treatment of
schizophrenia. The FDA approved the
company's Seroquel for the maintenance
treatment of patients with bipolar I disorder,
as adjunct to lithium or divalproexm, in 2008.
In the same year, AstraZeneca divested its
portfolio of over-the-counter (OTC) products
primarily sold in Sweden to GlaxoSmithKline
(GSK) for approximately $253 million.
2007 Contracts/Agreements
AstraZeneca entered into collaboration
agreements during the early 2007 with BristolMyers Squibb (BMS) to develop and
commercialize two investigational compounds
being studied for the treatment of type 2
diabetes; and with Palatin Technologies to
discover, develop and commercialize small
molecule compounds that target melanocortin
receptors. In addition, AstraZeneca and
Palatin signed a licensing and research
collaboration agreement to discover, develop
and commercialize small molecule
compounds that target melanocortin receptors.
The company opened a new PR&D laboratory
in Bangalore, India, and set up the initial base
for its new Innovation Centre China (ICC) at
Shanghai's Zhangjiang Hi-Tech Park.
2006 Contracts/Agreements
In May, AstraZeneca and Epigenomics signed
an agreement to identify and analyze potential
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 40
AstraZeneca PLC
DNA methylation biomarker candidates to use
in AstraZeneca's oncology programs.
2005 Contracts/Agreements
The company signed a research collaboration
agreement with Torrent Pharma for
development of novel anti-hypertensive drug.
2005 Acquisitions/Mergers/Takeovers During 2005, Astra Tech, a subsidiary of
AstraZeneca, acquired Cresco Ti Systems
from its primary owners SEB Foretagsinvest,
Credit Suisse Innoventure Capital, and
Banque Cantonale Vaudoise. AstraZeneca
acquired KuDOS Pharmaceuticals, a
privately-owned UK biotechnology company
focused on the discovery and development of
oncology therapies based on the inhibition of
DNA repair. The FDA granted US marketing
approval for AstraZeneca's Symbicort
(budesonide/formoterol) for the maintenance
treatment of asthma in patients aged 12 years
and older, in mid-2006.
2003 Regulatory Approval
AstraZeneca received a second marketing
approval for Crestor in Canada in 2003.
Crestor was launched in the Netherlands later
that year. The company received Australian
and the FDA approvals for Iressa in the same
year. The company's Seroquel (quetiapine)
received FDA approval as a monotherapy and
adjunct therapy for the treatment of bipolar
disorder (manic-depressive illness) in 2004.
Further in 2004, the company sold its 50%
stake in Advanta to Syngenta.
2002 New Products/Services
In 2002, AstraZeneca launched the prostate
cancer treatment Zoladex LA (longer acting),
in Japan. Around the same time, it also gained
FDA approval for its new breast cancer drug
Faslodex Injection for the treatment of
hormone receptor positive metastatic breast
cancer in postmenopausal women.
1999 Incorporation/Establishment
AstraZeneca (or 'the company') was formed as
a result of the merger between Sweden-based
Astra and the UK firm Zeneca in 1999.
AstraZeneca PLC- SWOT Analysis
AstraZeneca PLC (AstraZeneca or 'the company') is a global biopharmaceutical
company that develops, manufactures, and markets prescription medicines.
Significant R&D capabilities, sustained revenue growth and widespread geographic
presence are the company’s major strengths, whereas increasing liabilities remains the
cause for concern. Strategic initiatives, positive outlook for global pharmaceutical
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 41
AstraZeneca PLC
industry and drug approvals are likely to offer growth opportunities to the company.
However, uncertain R&D outcomes, influx of generics and government regulations
are likely to affect its business operations.
AstraZeneca PLC- Strengths
Strengths-Widespread geographic presence reduces business
risks
AstraZeneca has a diversified geographic presence. The company has business
presence in countries across Europe, Asia-Pacific, Africa and the Americas. It
operates tablet and capsule formulation sites in the UK, Sweden, China, Puerto Rico
and the US and local/regional supply sites in Russia, Japan, Indonesia, Egypt, India,
Germany, Mexico and Brazil. The company also has major formulation sites in the
US, Sweden, France, Australia and the UK for the global supply of parenteral and/or
inhalation products. Geographically, the company classifies its business operations in
four regions: the Americas; Asia, Africa and Australasia; Rest of Europe; and the UK.
In FY2021, the Americas accounted for 37.5% of the company’s revenue, followed
by Asia, Africa and Australasia (32.9%), Rest of Europe (20.9%) and the UK (8.7%).
The company's widespread footprint reduces its exposure to risks associated with
operating in a particular market. It also provides AstraZeneca with benefits such as
cost reductions through economies of scale. In addition, this geographic diversity
provides proximity to customers, enabling the development of close relationships.
Strengths-Significant R&D capabilities and manufacturing and
supply resources
AstraZeneca has significant research and development (R&D) capabilities. The
company’s R&D activities focus on developing new medicines for the treatment of
various diseases. R&D capabilities include biologic medicines, including
immunotherapies and novel delivery devices, oligonucleotides, small molecules, and
other emerging drug platforms. As of December 2021, it had 177 projects in its
pipeline and five new molecular entities (NMEs) in its late-stage pipeline. It operated
three global R&D centres in Cambridge, the UK; Gaithersburg, the US; and
Gothenburg, Sweden, and several additional R&D sites. The company collaborates
with academia, patient groups, scientific organizations, industry, governments, and
other pharmaceutical companies to bring innovation and develop new medicines to
address unmet medical need. As of December 2021, the company currently has more
than 1000 collaborations and obtained patent protection in more than 90 countries
around the world. In FY2021, the company spent US$9,736 million on R&D, which
accounted for 26% of the company’s revenue. AstraZeneca's significant R&D
capabilities and manufacturing and supply resources help it in manufacturing its
product efficiently that caters to unmet needs of its large customer base.
Strengths-Sustained revenue growth attracts new and potential
investors
AstraZeneca exhibited a strong revenue growth during the review period. In FY2021,
the company reported revenue of US$37,417 million as compared to US$26,617
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 42
AstraZeneca PLC
million in FY2020, indicating a growth of 40.6%. Sales were increased primarily due
to incremental growth of Product Sales revenue by US$36,541 million and
Collaboration revenue of US$876 million. Strong growth in revenue helps the
company gain investors' confidence and improving its ability to allocate adequate
funds for future growth prospects.
AstraZeneca PLC- Weaknesses
Weaknesses-Huge liabilities pose operational risk
AstraZeneca recorded an increase in its liabilities in the review year. Low liquidity
might prevent the company from meeting its short-term obligations efficiently. In
FY2021, the company reported current liabilities of US$22,594 million, compared to
US$20,307 million in FY2020, which shows an increase of 11.3% over the previous
year. This was due to an increase in lease liabilities, borrowings and trade and other
payables. In FY2021, the company reported current ratio of 1.1. Such a significant
increase in liabilities could affect the company’s credibility in the market and pose an
operational risk in terms of raising money for investment purposes.
AstraZeneca PLC- Opportunities
Opportunities-Drug approvals likely to help the company in
generating incremental revenue
Periodic drug approvals enable the company to invent and develop new formulas,
technologies and solutions in the fast-growing pharmaceutical industry. In November
2022, the company and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) received
approval in the European Union (EU) as monotherapy. The medicine can be used for
the treatment of adult patients with advanced HER2-positive gastric or
gastroesophageal junction (GEJ) adenocarcinoma. In the same month, the company's
COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), received full Marketing
Authorisation (MA) in the European Union (EU). In September 2022, the company
Koselugo (selumetinib) received approval in Japanese market. The medicine can be
used for the treatment of paediatric patients three years of age and older with
plexiform neurofibromas in neurofibromatosis type 1 (NF1) with clinical symptoms,
such as pain and disfigurement.
Opportunities-Strategic acquisitions are likely to help the company
in expanding its presence in market
AstraZeneca is enhancing its product and services through strategic collaborations and
agreements which in turn enhances its revenue and profitability. In August 2022, the
company acquired TeneoTwo, Inc. (TeneoTwo). The acquisition includes Phase I
clinical-stage CD19/CD3 T-cell engager, and TNB-486, an under evaluation in
relapsed and refractory B-cell non-Hodgkin lymphoma. TNB-486 is expected to be
used as a potential new medicine for B-cell haematologic malignancies for
AstraZeneca.
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 43
AstraZeneca PLC
Opportunities-Positive outlook for global pharmaceutical industry
The global pharmaceuticals market has experienced healthy growth in recent years
and also expected to grow in the next few years. According to in-house research the
global pharmaceuticals market is forecast to reach a value of US$1,191.5 billion by
2024. The US accounted for 38.7% of the global pharmaceuticals market value,
followed by Asia-Pacific (28.9%), Europe (23.1%), Middle East (2.5%) and rest of
the world (6.8%). The company offers pharmaceutical products globally. Thus, it
could benefit from the growing pharmaceutical industry, which in turn will help drive
the company's financial and operational growth.
AstraZeneca PLC- Threats
Threats-Uncertain R&D outcomes
Adverse or inconclusive results from clinical trials or preclinical testing may
substantially delay or halt the development of AstraZeneca’s various product
candidates, consequently affecting its timeliness for profitability. The outcome of
clinical trials is always a subject of uncertainty. After the discovery of a new
compound, a substantial amount of money and a great deal of time need to be invested
to successfully launch a new product. Moreover, it may become necessary to
discontinue clinical development if the effectiveness of a drug is not proven as
initially expected, or if serious adverse effects arise. Pharmaceuticals are subject to
legal restrictions in every country and authorization from regulatory authorities is a
prerequisite for a product launch in every country. It is difficult to accurately foresee
when approvals for a new product could be obtained.
Threats-Influx of generics
The pharmaceutical industry across the world is expected to report patent expiries of
many innovative drugs in the next few years. As the demand for pharmaceuticals
grows, governments are exerting increasing pressure on doctors to prescribe cheaper
generic medicines. As a result, pharmaceutical manufacturers will be under pressure
to develop generic medicines. This makes companies undertake changes in their
operations such as deploying the scale and international sourcing capabilities to
secure lower prices and better margins on generics in a way in which legislation
typically does not permit branded products. An increase of generic penetration will
have a direct effect on prescription medicines. Influx of generics into the market could
affect the company’s revenue.
Threats-Regulation in different countries might hamper revenue
growth
AstraZeneca operates in a highly regulated industry, where a variety of statutes and
regulations are in place for the testing, manufacture, and sale of pharmaceutical
products. The company has to obtain regulatory approvals before commercializing its
products. The company’s products, research and development activities and
manufacturing processes are subject to various local, state, federal, foreign and
transnational laws and regulations. In the US, the FDA; in Europe, the European
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 44
AstraZeneca PLC
Medicines Agency (EMA); and in China, the State Food and Drug Administration
(SFDA) of China regulates the manufacture, safety and quality of pharmaceutical
products, the commercialization of new pharmaceutical products, and labelling and
record-keeping procedures. Receiving marketing approval for new pharmaceutical
drugs and medical devices from these regulatory agencies is time consuming and
expensive. Failure to comply with the present or future regulations related to clinical,
laboratory and manufacturing practices may result in delayed approval of drugs,
product recalls, and cancellation of permission to produce or sell the drugs. With
several products under development, the company faces challenges from its
competitors, which have obtained regulatory approvals for marketing. The company’s
inability to obtain or retain regulatory approvals on a timely basis could affect its
financial position.
NOTE:The above strategic analysis is based on in-house research and reflects the
publishers opinion only
AstraZeneca PLC- Key Competitors
GSK plc.
Hikma Pharmaceuticals PLC
Actelion Pharmaceuticals Ltd
Merck KGaA
Novartis AG
Teva Pharmaceutical Industries Limited
AstraZeneca PLC- Key Employees
AstraZeneca PLC- Key Employees
Name
Job Title
Board Level Since Age Biography
Pascal
Chief Executive
Executive 2012 63 Mr. Soriot is the Director
Soriot
Officer
Board
and Chief Executive
Officer at AstraZeneca. He
joined the company from
Roche AG, where he
served as the Chief
Operating Officer of
pharmaceuticals division
from 2010 to 2012. Prior to
that, Mr. Soriot was the
Chief Executive Officer of
Genentech. He has worked
in senior management roles
in the pharmaceutical
industry since 1986.
Aradhana Director
Executive 2021 48 Ms. Sarin has been the
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 45
AstraZeneca PLC
Sarin
Board
Philip
Broadley
Director
Deborah
DiSanzo
Director
Tony Mok Director
Diana
Layfield
Director
Sheri
McCoy
Director
Michel
Demare
Director
Leif
Chairman
Johansson
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Director and Chief
Financial Officer of the
company since 2021. Prior
to this, she served as the
Managing Director of
Healthcare Corporate and
Investment Banking at Citi
Global Banking.
Previously, she served as
Managing Director of
Healthcare Investment
Banking at UBS and JP
Morgan.
2017 61
2017 62
2019 62
2020 52
2017 63
2019 66
2012 71 Mr. Johansson is the
Chairman at AstraZeneca.
He served as the Chairman
LM Ericsson from 2011 to
2018. Previously, he served
as the Chief Executive
Officer of AB Volvo from
1997 to 2011, the Director
of Bristol-Myers Squibb
from 1998 to 2011 and the
Chief Executive Officer of
AB Electrolux from 1994
to 1997. Mr. Johansson
served as the Chairman of
the European Round Table
of Industrialists from 2009
to 2014 and the Chairman
Page 46
AstraZeneca PLC
of the Royal Swedish
Academy of Engineering
Sciences from 2012 to
2017. He also serves as a
member of the Royal
Swedish Academy of
Engineering Sciences and
European Round Table of
Industrialists, as a Member
of the Council of Advisors,
Boao Forum for Asia and
holds board positions at
Autoliv, Inc and Ecolean
AB.
Andreas
Rummelt
Director
Euan
Ashley
Director
Marcus
Director
Wallenberg
Anna Manz Director
Nazneen
Rahman
Director
Ruud
Executive Vice
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Non
Executive
Board
Senior
2021 66
2020 51
1999 65 Mr. Wallenberg has been a
Director at AstraZeneca
since 1999. He has
international business
experience across a range
of industry sectors,
including the
pharmaceutical industry
from his directorship with
Astra prior to 1999. He is
the Chairman of
Skandinaviska Enskilda
Banken, AB Electrolux,
Saab, LKAB and
Foundation Asset
Management. He is a
member of the boards of
Investor, Temasek
Holdings Limited and the
Knut and Alice Wallenberg
Foundation.
2023
2017 55
2019
Mr. Dobber has been the
Page 47
AstraZeneca PLC
Dobber
President Management
BioPharmaceuticals
Business
Marc
Dunoyer
Chief Strategy
Officer
Sanjeev
Panchal
Adrian
Managing Director Senior
2023
Management
Secretary
Senior
2009
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Senior
2021
Management
Executive Vice President of
BioPharmaceuticals
Business at AstraZeneca
since 2019. Prior to this, he
served as the Executive
Vice President of North
America at the company.
Previously, he served as the
Executive Vice President of
Europe and was a Regional
Vice President of
AstraZeneca's European,
Middle East and African
division, and prior to that
he was a Regional Vice
President for the company's
Asia Pacific region. Mr.
Dobber joined AstraZeneca
in 1997 in the Netherlands
and held a number of
commercial roles. Mr.
Dobber also served as an
Executive Committee
Member of EFPIA
(European Federation of
Pharmaceutical Industries
and Associations) and the
Chairman of the Asia
division of Pharmaceutical
Research and
Manufacturers of America.
Mr. Dunoyer has been the
Chief Strategy Officer and
Chief Executive Officer of
Alexion at AstraZeneca
since 2021. Prior to this, he
served as the Chief
Financial Officer of the
company. Previously, he
served at Roussel Uclaf,
Hoechst Marion Roussel
and GSK. He also served as
Executive Vice-President,
Global Product and
Portfolio Strategy from
June to October 2013.
Page 48
AstraZeneca PLC
Charles
Noel
KEMP
Leon Wang Executive Vice
President International
Katarina
President Ageborg
AstraZeneca AB
Management
David
Executive Vice
Fredrickson President Oncology Business
Unit
Pam Cheng Executive Vice
President Operations and
Information
Technology
Senior
2017
Management
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Senior
2017
Management
Senior
2017
Management
Senior
2015
Management
Ms. Ageborg has been the
Executive Vice-President
of Sustainability and Chief
Compliance Officer at
AstraZeneca. Previously,
she led the global
Intellectual Property
function from 2008 to 2011
and served as the President
of AstraZeneca AB,
Sweden. Since joining
AstraZeneca in 1998, Ms.
Ageborg has held a series
of senior legal roles
supporting commercial,
regulatory and intellectual
property. Prior to
AstraZeneca, she worked as
a lawyer on both civil and
criminal cases.
Ms. Cheng has been the
Executive Vice President,
Operations and Information
Technology at AstraZeneca
since 2015. She has spent
14 years in Global
Manufacturing and Supply
Chain roles at Merck/MSD.
Ms. Cheng was Head of
Global Supply Chain
Management and Logistics
at Merck from 2006 to
2011 and led the
transformation of Merck
supply chains across the
global supply network.
Most recently, she was
President of MSD China.
Page 49
AstraZeneca PLC
Jeff Pott
Chief Human
Resources Officer
Senior
2021
Management
Prior to joining Merck, Ms.
Cheng held various
engineering and project
management positions at
Universal Oil Products
(UOP), Union Carbide
Corporation, and GAF
Chemicals.
Mr. Pott has been the
General Counsel and Chief
Human Resources Officer
of the company since 2021.
Prior to this, he spent five
years at the US legal firm
Drinker Biddle and Reath
LLP. Mr. Pott joined
AstraZeneca in 1995 and
worked in various litigation
roles.
Mene
Pangalos
Executive Vice
Senior
2019
President Management
BioPharmaceuticals
R&D
Susan
Executive Vice
Senior
2021
Galbraith President Management
Oncology Research
and Development
Iskra Reic Executive Vice
Senior
2019
President Management
Vaccines and
Immune Therapies
Source : GlobalData Research analysis / © GlobalData Research
AstraZeneca PLC- Company Statement
A statement by Mr. Leif Johansson, the Chairman of the company is given below. The
statement has been taken from the company’s 2021 annual report.
Continuing the successful implementation of AstraZeneca’s ‘growth through
innovation’ strategy in 2021 ensured we were able to deliver for patients around the
world and, thereby, our shareholders. More broadly, I am proud of the role we are
playing in contributing to the health of society and the planet. I am grateful to Pascal,
Senior Executive Team members and everyone in AstraZeneca, whose efforts made
this all possible.
A landmark year
2021 was a landmark year for the Company as we continued on our strong growth
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 50
AstraZeneca PLC
trajectory, with industry-leading R&D productivity, thirteen blockbuster medicines
and the acquisition of Alexion. We also delivered on our promise of broad and
equitable access to our COVID-19 vaccine. The positive news from our pipeline,
including FDA emergency use authorization of Evusheld and the approval of
Tezspire, support the outlook for 2022.
Reflecting increased confidence in future growth and cash generation, the Board
intends to increase the annualized dividend by $0.10 to $2.90, and has approved a
second interim dividend for 2021 of $1.97, payable in March 2022. This results in a
total dividend declared for 2021 of $2.87.
Alexion acquisition
Our positive outlook also stems, in part, from our transformative acquisition of
Alexion which completed in July. We are already seeing the benefits across
AstraZeneca in terms of scientific collaboration and expanding our Rare Disease
business which is accelerating delivery of our strategy.
Our new Chief Financial Officer, Aradhana Sarin joined the Board in August from
Alexion. Aradhana is a talented successor to Marc Dunoyer who stood down from the
Board to become Chief Executive Officer, Alexion and Chief Strategy Officer,
AstraZeneca. I am grateful to Marc for his significant contribution and the Board is
pleased he is staying on as a member of the Senior Executive Team (SET).
Also in August and following the Alexion acquisition, we welcomed Andreas
Rummelt to the Board as a Non-Executive Director. As a former member of the
Board of Alexion, he has deep knowledge of its rare diseases business and extensive
experience of the pharmaceutical industry including technical R&D, manufacturing
and quality assurance expertise.
Meeting global challenges
With the efforts that many, including AstraZeneca, are making to overcome COVID19, it’s time to plan for a world beyond the pandemic. I believe there are lessons we
can learn about how business, academia and government, by working together, can
overcome major global challenges such as the climate crisis and the provision of
sustainable healthcare.
The pandemic is also reinforcing the fact that companies succeed best when they are
truly part of society, when they are driven by their purpose; a purpose that is sustained
by the profit we make and our returns to you, our shareholders. This is at the heart of
how AstraZeneca operates and why I am so proud of our relentless pursuit of the
delivery of life-saving medicines and our wider contribution to society and the planet.
Succession planning
I will have served as a Director for ten years by April 2022. Typically, non-executive
directors would step down after nine years’ tenure, in line with UK corporate
governance best practice. Last year, the Board asked me to seek re-election at the
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 51
AstraZeneca PLC
AGM to lead the Board’s oversight of completion of the acquisition of Alexion.
Again this year, your Board believes it would be in the best interests of shareholders
for me to serve as Chair for one further year, to facilitate succession planning and the
transition to a new Chair, and has asked me to seek re-election at the AGM in April
2022. I am honoured and happy to accept the Board’s request again, mindful of my
intention to retire from the Board at the end of the AGM in 2023.
Succession planning for the role of Chair has continued to be a focus of the
Nomination and Governance Committee’s work during 2021, with a search that is
proceeding well led by Philip Broadley, senior independent Non-Executive Director.
Meeting again
In November, it was a pleasure to be able to meet in person to celebrate the unveiling
of our Discovery Centre in Cambridge, UK with HRH The Prince of Wales and
guests from across business, academia and government. While much can be achieved
by working and meeting virtually, there is also value in being able to meet in person.
For the first time in two years, we are planning to hold this year’s AGM in person and
I look forward to meeting as many of you there as possible.
AstraZeneca PLC- Locations & Subsidiaries
Head office
1 Francis Crick Avenue
Cambridge
United Kingdom
CB2 0AA
44 20 73045000
Other Locations & Subsidiaries
AstraZeneca PLC, Other locations
1 Francis Crick Avenue
Cambridge
United Kingdom
CB2 0AA
44 20 73045000
Source : GlobalData Research analysis / © GlobalData Research
AstraZeneca PLC, Subsidiaries
AstraZeneca Canada Inc
1004 Middlegate Road
Mississauga
Ontario
L4Y1M4
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 52
AstraZeneca PLC
Canada
1 905 2777111
AstraZeneca A/S
Arne Jacobsens Alle 13
Copenhagen
Greenland
2300
Denmark
45 43 666462
AstraZeneca AS
Grenseveien 92
Oslo
Faroe Islands
0601
Norway
47 2 10064000
AstraZeneca Pharma Poland Sp. z o.o.
Warszawa
02676
Poland
48 22 8743500
Summarized Statement
AstraZeneca PLC, Annual Statements
Parameter Name
Currency 2018
2019
2020
2021
2022
Income Statements
Total Revenue
Gross Profit
Operating Income
Net Income
Diluted Normalized
EPS
USD
USD
USD
USD
USD
22090.00 24384.00 26617.00 37417.00 44351.00
17844.00 19560.00 21347.00 27875.00 35702.00
3387.00 2924.00 5162.00 1056.00 3757.00
2155.00 1335.00 3196.00
112.00 3288.00
00.85
01.49
01.89
02.23
04.05
Balance Sheet
Total Current Assets
Total Assets
Total Current
Liabilities
Published: 24 Oct 2023
Extracted: 29 Oct 2023
USD
USD
15591.00 15563.00 19544.00 26244.00 22593.00
60651.00 61377.00 66729.00 105363.00 96483.00
USD
16292.00 18117.00 20307.00 22594.00 26293.00
Page 53
AstraZeneca PLC
Total Liabilities
Total Equity
Total Common Shares
Outstanding
USD
USD
48183.00 48250.00 51107.00 66095.00 59446.00
12468.00 13127.00 15622.00 39268.00 37037.00
USD
1267.04 1312.14 1312.67
1549.40 1549.80
USD
2618.00 2969.00 4799.00
5963.00 9808.00
Cash Flow
Cash from Operating
Activities
Cash from Investing
Activities
Cash from Financing
Activities
Net Change in Cash
USD
USD
USD
963.00 -657.00 -285.00 -11058.00 -2960.00
-2044.00 -1765.00 -2203.00
1499.00
3649.00 -6823.00
552.00 2323.00 -1508.00
-55.00
Detailed Statement
AstraZeneca PLC, Full Annual Statements
Parameter Name
Currency 2018
2019
2020
2021
2022
Income Statements
Revenue
Cost of Revenue, Total
Selling/ General/
Admin. Expenses,
Total
Research &
Development
Depreciation/
Amortization
Unusual Expense
(Income)
Other Operating
Expenses, Total
Total Operating
Expense
Other, Net
Net Income Before
Taxes
Provision for Income
Taxes
Net Income After
Taxes
Minority Interest
Net Income Before
Published: 24 Oct 2023
Extracted: 29 Oct 2023
USD
USD
22090.00 24384.00 26617.00 37417.00 44351.00
4246.00 4824.00 5270.00 9542.00 8649.00
USD
8479.00 8964.00 9338.00 11519.00 13512.00
USD
5266.00 5320.00 6094.00
8519.00 9612.00
USD
1945.00 1812.00 1897.00
3044.00 4094.00
USD
-953.00
863.00 -763.00
3846.00 5071.00
USD
-280.00 -323.00 -381.00
-109.00 -344.00
USD
18703.00 21460.00 21455.00 36361.00 40594.00
USD
-619.00 -610.00 -530.00
-502.00 -441.00
USD
1993.00 1548.00 3916.00
-265.00 2501.00
USD
-57.00
321.00
772.00
-380.00 -792.00
USD
2050.00 1227.00 3144.00
115.00 3293.00
USD
USD
105.00 108.00
52.00
2155.00 1335.00 3196.00
-03.00 -05.00
112.00 3288.00
Page 54
AstraZeneca PLC
Extra. Items
Total Extraordinary
Items
Income Available to
Com Excl ExtraOrd
Income Available to
Com Incl ExtraOrd
Dilution Adjustment
Diluted Net Income
Diluted Weighted
Average Shares
Diluted EPS Excluding
ExtraOrd Items
DPS - Common Stock
Primary Issue
USD
00.00
00.00
00.00
00.00
00.00
USD
2155.00 1335.00 3196.00
112.00 3288.00
USD
2155.00 1335.00 3196.00
112.00 3288.00
USD
USD
00.00
00.00
00.00
2155.00 1335.00 3196.00
00.00
00.00
112.00 3288.00
USD
1267.00 1301.00 1313.00
1427.00 1560.00
USD
01.70
01.03
02.43
00.08
02.11
USD
02.75
02.89
02.83
02.84
02.89
Balance Sheet
Cash
Cash & Equivalents
Short Term
Investments
Cash and Short Term
Investments
Accounts Receivable Trade, Net
Total Receivables, Net
Total Inventory
Prepaid Expenses
Other Current Assets,
Total
Property/ Plant/
Equipment, Total Gross
Accumulated
Depreciation, Total
Property/ Plant/
Equipment, Total - Net
Goodwill, Net
Intangibles, Net
Long Term
Investments
Note Receivable Long Term
Other Long Term
Assets, Total
Published: 24 Oct 2023
Extracted: 29 Oct 2023
USD
USD
USD
893.00 755.00 1182.00
3938.00 4614.00 6650.00
849.00
849.00
160.00
1461.00 1411.00
4868.00 4755.00
69.00
239.00
USD
5680.00 6218.00 7992.00
6398.00 6405.00
USD
2995.00 3813.00 3956.00
6324.00 7508.00
USD
USD
USD
4345.00 5181.00 5651.00
2890.00 3193.00 4024.00
1436.00 865.00 1735.00
8795.00 9923.00
8983.00 4699.00
1512.00 1329.00
USD
1240.00
106.00
142.00
556.00
237.00
USD
14639.00 15852.00 17110.00 18495.00 17192.00
USD
-7218.00 -7517.00 -8193.00 -8324.00 -7743.00
USD
7421.00 8335.00 8917.00 10171.00 9449.00
USD
USD
11707.00 11668.00 11845.00 19997.00 19820.00
21959.00 20833.00 20947.00 42387.00 39307.00
USD
922.00 1459.00 1147.00
USD
515.00
USD
348.00
325.00
2536.00 3171.00 4004.00
1237.00 1142.00
504.00
592.00
4823.00 3580.00
Page 55
AstraZeneca PLC
Accounts Payable
Accrued Expenses
Notes Payable/ Short
Term Debt
Current Port. of LT
Debt/ Capital Leases
Other Current
liabilities, Total
Long Term Debt
Capital Lease
Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Other Liabilities, Total
Common Stock, Total
Additional Paid-In
Capital
Retained Earnings
(Accumulated Deficit)
Total Liabilities &
Shareholders' Equity
USD
USD
USD
1720.00 1774.00 2350.00
5148.00 5085.00 4994.00
160.00
154.00
370.00
2824.00 2550.00
8079.00 8303.00
294.00
261.00
USD
1594.00 1856.00 2016.00
1599.00 5281.00
USD
7670.00 9248.00 10577.00
9798.00 9898.00
USD
USD
17359.00 15730.00 17505.00 28134.00 22965.00
00.00
487.00
489.00
754.00
725.00
USD
USD
USD
USD
USD
USD
17359.00 16217.00 17994.00 28888.00 23690.00
19113.00 18227.00 20380.00 30781.00 29232.00
3286.00 2490.00 2918.00 6206.00 2944.00
1576.00 1469.00
16.00
19.00
21.00
9670.00 9957.00 9872.00 8388.00 6498.00
317.00 328.00 328.00
387.00 387.00
USD
4427.00 7941.00 7971.00 35126.00 35155.00
USD
7724.00 4858.00 7323.00
USD
3755.00 1495.00
60651.00 61377.00 66729.00 105363.00 96483.00
Cash Flow
Net Income/ Starting
Line
Depreciation/
Depletion
Non-Cash Items
Changes in Working
Capital
Capital Expenditures
Other Investing Cash
Flow Items, Total
Financing Cash Flow
Items
Total Cash Dividends
Paid
Issuance (Retirement)
of Stock, Net
Issuance (Retirement)
of Debt, Net
Foreign Exchange
Effects
Published: 24 Oct 2023
Extracted: 29 Oct 2023
USD
1993.00 1548.00 3916.00
-265.00 2501.00
USD
3753.00 3762.00 3149.00
6530.00 5480.00
USD
-1276.00 -103.00 -332.00
USD
-1852.00 -2238.00 -1934.00
USD
-1371.00 -2460.00 -2606.00 -2200.00 -2571.00
USD
2334.00 1803.00 2321.00 -8858.00 -389.00
USD
USD
USD
USD
USD
-67.00
04.00 -101.00
141.00
542.00
-443.00 1285.00
-178.00 -1047.00
-3484.00 -3592.00 -3572.00 -3856.00 -4364.00
34.00 3525.00
30.00
1473.00 -1702.00 1440.00
-38.00
05.00
12.00
29.00
29.00
7654.00 -1441.00
-62.00
Page 56
-80.00
AstraZeneca PLC
Cash Interest Paid
Cash Taxes Paid
USD
USD
676.00 774.00 733.00
537.00 1118.00 1562.00
721.00 849.00
1743.00 1623.00
Summarized Interim Statement
AstraZeneca PLC, Summarized Interim Statements
Income Statements Currency
Total Revenue
Gross Profit
Operating Income
Net Income
Diluted Normalized
EPS
USD
USD
USD
USD
Sep-2022 (3 Dec-2022 (3 Mar-2023 Jun-2023 (3
Months)
Months)
(3 Months) Months)
10982.00
11207.00
10879.00
11416.00
8864.00
8790.00
9097.00
9491.00
1245.00
1094.00
2549.00
2456.00
1640.00
901.00
1803.00
1818.00
USD
01.00
00.91
01.35
01.01
USD
USD
20224.00
94185.00
22593.00
96483.00
22266.00
96687.00
22839.00
96543.00
USD
24850.00
26293.00
24860.00
26375.00
USD
USD
59051.00
35134.00
59446.00
37037.00
60898.00
35789.00
59151.00
37392.00
USD
1549.51
1549.80
1549.85
1549.88
USD
7410.00
9808.00
3133.00
4851.00
USD
-2711.00
-2960.00
-1246.00
-1766.00
USD
-6465.00
-6823.00
-2031.00
-3550.00
USD
-1852.00
-55.00
-155.00
-512.00
Balance Sheet
Total Current Assets
Total Assets
Total Current
Liabilities
Total Liabilities
Total Equity
Total Common
Shares Outstanding
Cash Flow
Cash from Operating
Activities
Cash from Investing
Activities
Cash from Financing
Activities
Net Change in Cash
Detailed Interim Statement
AstraZeneca PLC, Detailed Interim Statement
Income Statements
Revenue
Cost of Revenue, Total
Selling/ General/
Admin. Expenses, Total
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Currency
USD
USD
USD
Sep-2022 Dec-2022 Mar-2023 Jun-2023
(3 Months) (3 Months) (3 Months) (3 Months)
10982.00 11207.00 10879.00 11416.00
2118.00
2417.00
1782.00
1925.00
3353.00
3469.00
3196.00
Page 57
3592.00
AstraZeneca PLC
Research &
Development
Depreciation/
Amortization
Unusual Expense
(Income)
Other Operating
Expenses, Total
Total Operating
Expense
Net Income Before
Taxes
Provision for Income
Taxes
Net Income After Taxes
Minority Interest
Net Income Before
Extra. Items
Income Available to
Com Excl ExtraOrd
Income Available to
Com Incl ExtraOrd
Diluted Net Income
Diluted Weighted
Average Shares
Diluted EPS Excluding
ExtraOrd Items
DPS - Common Stock
Primary Issue
USD
2357.00
2525.00
2299.00
2570.00
USD
979.00
1034.00
954.00
952.00
USD
1002.00
641.00
379.00
-285.00
USD
-72.00
27.00
-280.00
206.00
USD
9737.00
10113.00
8330.00
8960.00
USD
922.00
778.00
2262.00
2088.00
USD
-720.00
-124.00
458.00
268.00
USD
USD
1642.00
-02.00
902.00
-01.00
1804.00
-01.00
1820.00
-02.00
USD
1640.00
901.00
1803.00
1818.00
USD
1640.00
901.00
1803.00
1818.00
USD
1640.00
901.00
1803.00
1818.00
USD
1640.00
901.00
1803.00
1818.00
USD
1559.00
1560.00
1560.00
1560.00
USD
01.05
00.58
01.16
01.17
USD
00.00
01.97
00.00
00.91
USD
USD
4458.00
440.00
6166.00
239.00
6232.00
230.00
5664.00
148.00
USD
4898.00
6405.00
6462.00
5812.00
USD
9336.00
10521.00
10289.00
11092.00
USD
USD
10061.00
5078.00
11252.00
4699.00
10797.00
4967.00
11932.00
5051.00
USD
187.00
237.00
40.00
44.00
USD
9227.00
9449.00
9599.00
9624.00
USD
USD
19707.00
39585.00
19820.00
39307.00
20001.00
39291.00
19960.00
38326.00
Balance Sheet
Cash & Equivalents
Short Term Investments
Cash and Short Term
Investments
Accounts Receivable Trade, Net
Total Receivables, Net
Total Inventory
Other Current Assets,
Total
Property/ Plant/
Equipment, Total - Net
Goodwill, Net
Intangibles, Net
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 58
AstraZeneca PLC
Long Term Investments
Note Receivable - Long
Term
Other Long Term
Assets, Total
Payable/ Accrued
Notes Payable/ Short
Term Debt
Current Port. of LT
Debt/ Capital Leases
Other Current liabilities,
Total
Long Term Debt
Capital Lease
Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Other Liabilities, Total
Common Stock, Total
Additional Paid-In
Capital
Retained Earnings
(Accumulated Deficit)
Total Liabilities &
Shareholders' Equity
USD
1102.00
1142.00
1234.00
1143.00
USD
792.00
835.00
682.00
752.00
USD
3548.00
3337.00
3614.00
3899.00
17694.00
19040.00
19210.00
19738.00
USD
584.00
261.00
568.00
271.00
USD
5034.00
5281.00
3289.00
4516.00
USD
1538.00
1711.00
1793.00
1850.00
USD
23013.00
22965.00
26916.00
24329.00
USD
668.00
725.00
730.00
722.00
USD
USD
USD
USD
USD
USD
23681.00
29299.00
3479.00
20.00
7021.00
387.00
23690.00
29232.00
2944.00
21.00
6498.00
387.00
27646.00
31503.00
2795.00
22.00
5575.00
387.00
25051.00
29838.00
2800.00
24.00
4901.00
387.00
USD
35137.00
35155.00
35159.00
35163.00
USD
-390.00
1495.00
243.00
1842.00
USD
94185.00
96483.00
96687.00
96543.00
USD
1723.00
2501.00
2501.00
4350.00
USD
USD
4000.00
172.00
5480.00
542.00
5480.00
542.00
2778.00
14.00
USD
1515.00
1285.00
1285.00
-2291.00
USD
-2017.00
-2571.00
-2571.00
-1953.00
USD
-694.00
-389.00
-389.00
187.00
USD
-1047.00
-1047.00
-1047.00
-840.00
USD
-4364.00
-4364.00
-4364.00
-3069.00
USD
11.00
29.00
29.00
08.00
USD
-1065.00
-1441.00
-1441.00
351.00
Cash Flow
Net Income/ Starting
Line
Depreciation/ Depletion
Non-Cash Items
Changes in Working
Capital
Capital Expenditures
Other Investing Cash
Flow Items, Total
Financing Cash Flow
Items
Total Cash Dividends
Paid
Issuance (Retirement) of
Stock, Net
Issuance (Retirement) of
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 59
AstraZeneca PLC
Debt, Net
Foreign Exchange
Effects
Cash Interest Paid
Cash Taxes Paid
USD
-86.00
-80.00
-80.00
-47.00
USD
USD
608.00
1335.00
849.00
1623.00
849.00
1623.00
483.00
1061.00
Capital Market Ratios
AstraZeneca PLC, Capital Market Ratios
Key Ratios
P/E (Price/Earnings) Ratio
EV/EBITDA (Enterprise Value/Earnings Before Interest, Taxes,
Depreciation and Amortization)
Enterprise Value/Sales
Enterprise Value/Operating Profit
Enterprise Value/Total Assets
Dividend Yield
Market Cap
Enterprise Value
Source : GlobalData Research analysis / © GlobalData Research
October 27,
2023
59.70
27.46
04.94
87.62
02.27
02.22
156912.50
180219.01
Interim Ratios
AstraZeneca PLC, Interim Ratios
Key Ratios
Unit/Currency
EPS (Earnings
USD
per Share)
Dividend per
USD
Share
Book Value
USD
per Share
Gross Margin %
Operating
Margin
Net Profit
Margin
%
%
Profit Markup %
PBIT Margin
%
(Profit Before
Published: 24 Oct 2023
Extracted: 29 Oct 2023
September December March June Ratio Type
- 2022
- 2022
- 2023 2023
Equity
01.05
00.58 01.16 01.17
Ratios
Equity
00.00
01.97 00.00 00.91
Ratios
Equity
22.67
23.90 23.09 24.13
Ratios
Profitability
80.71
78.43 83.62 83.14
Ratios
Profitability
11.34
09.76 23.43 21.51
Ratios
Profitability
14.93
08.04 16.57 15.93
Ratios
Profitability
418.51
363.67 510.49 493.04
Ratios
Profitability
35.17
51.89 25.04 29.39
Ratios
Page 60
AstraZeneca PLC
Interest & Tax)
PBT Margin
(Profit Before %
Tax)
Operating
Costs (% of
%
Sales)
Administration
Costs (% of
%
Sales)
Interest Costs
%
(% of Sales)
Profitability
Ratios
08.40
06.94
20.79
18.29
88.66
90.24
76.57
78.49 Cost Ratios
30.53
30.95
29.38
31.47 Cost Ratios
01.27
01.13
01.33
01.46 Cost Ratios
Liquidity
Ratios
Liquidity
Quick Ratio
Absolute
00.61
00.68 00.70 00.67
Ratios
Debt to Equity
Leverage
Absolute
00.83
00.79 00.88 00.80
Ratio
Ratios
Net Debt to
Leverage
Absolute
00.71
00.62 00.71 00.65
Equity
Ratios
Debt to Capital
Leverage
Absolute
00.42
00.42 00.44 00.43
Ratio
Ratios
Interest
Leverage
Absolute
2771.03 4582.80 1884.35 2018.69
Coverage Ratio
Ratios
Source : GlobalData Research analysis / © GlobalData Research
Current Ratio Absolute
00.81
00.86
00.90
00.87
Annual Ratios
AstraZeneca PLC, Annual Ratios
Ratio Type
Growth
Ratios
Growth
Ratios
Growth
Ratios
Growth
Ratios
Growth
Ratios
Growth
Ratios
Equity
Ratios
Equity
Key Ratios
Unit/Currency 2022
Sales Growth
%
Operating
%
Income Growth
EBITDA
%
Growth
Net Income
%
Growth
EPS Growth
%
Working
%
Capital Growth
EPS (Earnings
USD
per Share)
Dividend per
USD
Published: 24 Oct 2023
Extracted: 29 Oct 2023
2021
2020
2019
2018
18.53 40.58 09.16 10.38 -01.67
255.78 -79.54 76.54 -13.67 -07.89
21.76 -08.72 24.30 -06.36 06.36
2835.71 -96.50 139.40 -38.05 -28.19
81.71 17.96 27.14 73.89 -37.64
-201.37
-70.13 264.34 -78.32
578.37
04.05 02.23 01.89 01.49 00.85
02.89 02.84 02.83 02.89 02.75
Page 61
AstraZeneca PLC
Ratios
Equity
Ratios
Equity
Ratios
Equity
Ratios
Profitability
Ratios
Profitability
Ratios
Profitability
Ratios
Profitability
Ratios
Share
Dividend Cover Absolute
Book Value per
USD
Share
Cash Value per
USD
Share
Gross Margin
Operating
Margin
Net Profit
Margin
Profit Markup
23.90 25.34 11.90 10.00 09.84
03.98 04.08 05.97 04.09 03.81
%
80.50 74.50 80.20 80.22 80.78
%
08.47 02.82 19.39 11.99 15.33
%
07.41 00.30 12.01 05.47 09.76
%
412.79 292.13 405.07 405.47 420.25
PBT Margin
Profitability
(Profit Before %
Ratios
Tax)
Profitability Return on
%
Ratios
Equity
Return on
Profitability
Capital
%
Ratios
Employed
Profitability Return on
%
Ratios
Assets
Profitability Return on Fixed
%
Ratios
Assets
Return on
Profitability
Working
%
Ratios
Capital
Operating Costs
Cost Ratios
%
(% of Sales)
Administration
Cost Ratios Costs (% of
%
Sales)
Liquidity
Current Ratio Absolute
Ratios
Liquidity
Quick Ratio
Absolute
Ratios
Liquidity
Cash Ratio
Absolute
Ratios
Leverage Debt to Equity
Absolute
Ratios
Ratio
Leverage Net Debt to
Absolute
Ratios
Equity
Leverage Debt to Capital Absolute
Published: 24 Oct 2023
Extracted: 29 Oct 2023
01.40 00.78 00.67 00.51 00.31
05.64 -00.71 14.71 06.35 09.02
08.88 00.29 20.46 10.17 17.28
05.35 01.28 11.12 06.76 07.64
03.26 00.13 04.99 02.19 03.48
38.30 11.06 59.84 37.12 45.05
-101.54 28.93
676.54 114.49 483.17
91.53 97.18 80.61 88.01 84.67
30.47 30.79 35.08 36.76 38.38
00.86 01.16 00.96 00.86 00.96
00.68 00.76 00.76 00.68 00.78
00.23 00.28 00.39 00.30 00.30
00.79 00.78 01.30 01.39 01.53
00.62 00.62 00.79 00.91 01.08
00.44 00.44 00.57 00.58 00.61
Page 62
AstraZeneca PLC
Ratios
Efficiency
Ratios
Efficiency
Ratios
Efficiency
Ratios
Efficiency
Ratios
Efficiency
Ratios
Efficiency
Ratios
Ratio
Asset Turnover Absolute
Fixed Asset
Turnover
Inventory
Turnover
Current Asset
Turnover
Capital
Employed
Turnover
Working
Capital
Turnover
Revenue per
Employee
Net Income per
Employee
00.44 00.43 00.42 00.40 00.36
Absolute
04.52 03.92 03.09 03.10 02.94
Absolute
01.26 01.47 01.46 01.59 01.43
Absolute
01.82 01.63 01.52 01.57 01.54
Absolute
00.63 00.45 00.57 00.56 00.50
Absolute
-11.99 10.25 -34.88 -09.55 -31.51
Efficiency
USD
531149.70 00.00 00.00
Ratios
Efficiency
USD
39377.25 00.00 00.00
Ratios
Efficiency
Capex to Sales %
05.80 05.88 09.79
Ratios
Efficiency
R&D to Sales %
21.67 22.77 22.90
Ratios
Source : GlobalData Research analysis / © GlobalData Research
00.00 00.00
00.00 00.00
10.09 06.21
21.82 23.84
Disclaimer:
All Rights Reserved.
This information has been extracted from MarketLine by a registered user
No part of this publication may be reproduced, stored in a retrieval system or
transmitted in any form by any means, electronic, mechanical, photocopying,
recording or otherwise, without the prior permission of the publisher, MarketLine.
The facts of this report are believed to be correct at the time of publication but cannot
be guaranteed. Please note that the findings, conclusions and recommendations that
MarketLine delivers will be based on information gathered in good faith from both
primary and secondary sources, whose accuracy we are not always in a position to
guarantee. As such MarketLine can accept no liability whatever for actions taken
based on any information that may subsequently prove to be incorrect.
Published: 24 Oct 2023
Extracted: 29 Oct 2023
Page 63